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Abstract 
A common feature of many neuropathies is axon degeneration.  While the 
reasons for degeneration differ greatly, the process of degeneration itself is 
similar in most cases.  Axon degeneration after axotomy is termed ‘Wallerian 
degeneration,’ whereby injured axons rapidly fragment and disappear after a 
short period of latency (Waller, 1850).  Wallerian degeneration was thought to be 
a passive process until the discovery of the Wallerian degeneration slow (Wlds) 
mouse mutant.  In these mice, axons survive and function for weeks after nerve 
transection. Furthermore, when the full-length protein is inserted into mouse 
models of disease with an axon degeneration phenotype (such as progressive 
motor neuronopathy), Wlds is able to delay disease onset (for a review, see 
Coleman, 2005).  Wlds has been cloned and was found to be a fusion event of 
two neighboring genes: Ube4b, which encodes an ubiquitinating enzyme, and 
NMNAT-1 (nicotinamide mononucleotide adenylyltransferase-1), which encodes 
a key factor in NAD (nicotinamide adenine dinucleotide) biosynthesis, joined by a 
54 nucleotide linker span (Mack et al., 2001).  
 To address the role of Wlds domains in axon protection and to 
characterize the subcellular localization of Wlds in neurons, our lab developed a 
novel method to study Wallerian degeneration in Drosophila in vivo (MacDonald 
et al., 2006).  Using this method, we have discovered that mouse Wlds can also 
protect Drosophila axons for weeks after acute injury, indicating that the 
molecular mechanisms of Wallerian degeneration are well conserved between 
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mouse and Drosophila.  This observation allows us to use an easily manipulated 
genetic model to move the Wlds field forward; we can readily identify what Wlds 
domains give the greatest protection after injury and where in the neuron 
protection occurs.  In chapter two of this thesis, I identify the minimal domains of 
Wlds that are needed for protection of severed Drosophila axons: the first 16 
amino acids of Ube4b fused to Nmnat1.  Although Nmnat1 and Wlds are nuclear 
proteins, we find evidence of a non-nuclear role in axonal protection in that a 
mitochondrial protein, Nmnat3, protects axons as well as Wlds. 
 In chapter 3, I further explore a role for mitochondria in Wlds-mediated 
severed axon protection and find the first cell biological changes seen in a Wlds-
expressing neuron.  The mitochondria of Wlds- and Nmnat3-expressing neurons 
are more motile before injury.  We find this motility is necessary for protection as 
suppressing the motility with miro heterozygous alleles suppresses Wlds-
mediated axon protection.  We also find that Wlds- and Nmnat3- expressing 
neurons show a decrease in calcium fluorescent reporter, gCaMP3, signal after 
axotomy.  We propose a model whereby Wlds, through production of NAD in the 
mitochondria, leads to an increase in calcium buffering capacity, which would 
decrease the amount of calcium in the cytosol, allowing for more motile 
mitochondria.  In the case of injury, the high calcium signal is buffered more 
quickly and so cannot signal for the axon to die. 
 Finally, in chapter 4 of my thesis, I identify a gene in an EMS-based 
forward genetic screen which can suppress Wallerian degeneration.  This mutant 
	   vii	  
is a loss of function, which, for the first time, definitively demonstrates that 
Wallerian degeneration is an active process.  The mammalian homologue of the 
gene encodes a mitochondrial protein, which in light of the rest of the work in this 
thesis, highlights the importance of mitochondria in neuronal health and disease. 
In conclusion, the work presented in this thesis highlights a role for 
mitochondria in both Wlds-mediated axon protection and Wallerian degeneration 
itself.  I identified the first cell biological changes seen in Wlds-expressing 
neurons and show that at least one of these is necessary for its protection of 
severed axons.  I also helped find the first Wallerian degeneration loss-of-
function mutant, showing Wallerian degeneration is an active process, mediated 
by a molecularly distinct axonal degeneration pathway.  The future of the axon 
degeneration field should focus on the mitochondria as a potential therapeutic 
target. 
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Wallerian Degeneration: an overview 
Neurodegenerative disorders are caused by many factors, but most result 
in axon degeneration through a process which is not well-characterized at a 
molecular level.  In 1850, Augustus Waller observed that when an axon was 
severed, it rapidly fragmented after a short period of latency, and was eventually 
cleared from the site of injury (Waller, 1850).  This process, termed ‘Wallerian 
degeneration’, was long thought to be a passive process of an axon wasting 
away due to a lack of nutrient supply from the cell body.  However, the thought 
that Wallerian degeneration was passive was changed upon the finding of 
spontaneous mouse mutant Wallerian degeneration slow (Wlds) (Lunn et al., 
1989).  In these mice, axons survived and functioned for weeks after transection, 
suggesting that Wallerian degeneration is in fact an active process that can be 
inhibited (Lunn et al., 1989).   
     As degeneration following transection can be inhibited by Wlds, the possibility 
arose that similar forms of axon degeneration, seen in other neurodegenerative 
diseases, may also be inhibited in Wlds mice.  To address this question, Wlds 
mice were crossed with various mouse models of neurodegenerative disease. 
Interestingly, Wlds was found to delay the onset of several neurological diseases 
such as Parkinson’s (Sajadi et al., 2004), gracile axonal dystrophy (Mi et al., 
2005), progressive motor neuropathy (Ferri et al., 2003), and amyotrophic lateral 
sclerosis (Fischer et al., 2005).  Wlds-expressing neurons were also found to be 
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resistant to neurotoxic chemicals like vincristine (Wang et al., 2001) and taxol 
(Wang et al., 2002).  The ability of Wlds to protect against such varied forms of 
axon degeneration led to the belief that the molecular mechanisms of 
degeneration were much more similar than originally thought.  Thus, 
understanding how the Wlds protein protects axons is imperative for an overall 
understanding of how axon degeneration occurs.   
     To begin to understand axon degeneration, it was of utmost importance to 
identify the mutation that caused the Wlds phenotype in mice.  The Wld locus 
was mapped to the 4th chromosome, and was found to be a spontaneous tandem 
triplication resulting in an in-frame fusion protein (Figure 1-1) (Conforti et al., 
2000). The chimeric protein consists of the first 70 amino acids of Ube4b, an E4 
ligase, and the full-length Nmnat1, a key enzyme in the NAD+ synthesis 
pathway, joined by an 18 amino acid linker sequence (Mack et al., 2001).  
     The unique 18 amino acid linker domain enabled researchers to develop an 
antibody to specifically recognize Wlds, which revealed that Wlds localized to the 
nucleus of neurons (Mack et al., 2001). This result was unexpected since axon 
transection removes the cell body from Wlds-protected axons.  It is possible that 
low levels of axonal Wlds may be present below detection level; however, the 
prevailing thought is that a signal must be constitutively sent from the nucleus to 
the axon to prevent degeneration when the axon is cut.  The identity of the signal 
and how it keeps the axon alive remains a mystery, but the nature of the domains 
of Wlds has given rise to several hypotheses as to how Wlds is acting.   
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Based on the information above and several other findings, four main 
hypotheses have been proposed to explain the neuroprotective actions of Wlds 
(Mack et al., 2001; Gilley and Coleman, 2010).  (1) Wlds has a dominant-negative 
effect on the ubiquitin proteasome system through its N70 domain.  (2) The 
Nmnat1 domain produces an excess of NAD+, which could protect axons by 
providing them with excess energy to delay degeneration or by promoting NAD+-
dependent gene transcription.   (3) Wlds affects gene regulation through a yet 
unknown mechanism.  (4) Wlds compensates in the axon for the lack of an 
endogenous survival signal from the nucleus. It is possible that the protection of 
Wlds is due to a combination of one or more of the proposed hypotheses 
explained in detail below; none are mutually exclusive.  
 
(1) Wlds N70 Ube4b Domain and the Ubiquitin Proteasome System 
The ubiquitin proteasome system (UPS) is a quality control mechanism 
through which the cell can tag misfolded proteins for degradation and is also 
used for fine-tuning temporal resolution for proteins whose activity needs to be 
turned off quickly.  The UPS has also been implicated in neurodegeneration.  
The addition of proteasome inhibitors prior to axon injury profoundly delays 
Wallerian degeneration both in vitro and in vivo (Zhai et al., 2003).  The 
requirement for the inhibitor prior to injury, coupled with the knowledge that these 
inhibitors work very quickly, implies that the proteasome is involved in early 
stages of Wallerian degeneration.  Additionally the earliest observed step in 
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Wallerian degeneration, microtubule destabilization, is delayed when the 
proteasome is inhibited (Zhai et al., 2003).  Proteasome inhibitors cannot protect 
against microtubule destabilizing agents such as vincristine and colchine (Zhai et 
al., 2003), suggesting again that the proteasome acts upstream of microtubule 
destabilization.  Before a protein bound for degradation reaches the proteasome, 
it is first tagged with ubiquitin.  Therefore, protein ubiquitination is another step 
that could be involved in axon degeneration. 
The first domain of the Wlds gene encodes for the 70 N-terminal amino 
acids of Ube4b, a member of the E4 class of ubiquitin chain assembly factors.  
This portion of Ube4b, called N70, is insufficient for substrate ubiquitination, but 
is necessary for binding its substrates targeted for ubiquitination.  Therefore, it is 
thought that part of Wlds protection occurs through a dominant negative effect on 
the UPS, as Ube4b can bind proteins, but fails to process them for degradation.  
N70 may protect axons from degeneration by binding substrates destined for the 
proteasome whose degradation would normally initiate the cascade of 
degeneration events.  Because Wlds cannot ubiquitinate substrates, the 
proteasome would no longer recognize the molecules for degradation, thereby 
saving the axon from this catastrophic event. Ube4b, however, may also be 
important in neuronal integrity. 
 Ube4b is expressed in cardiac muscles during development; however, in 
the adult it is abundant in neurons (Kaneko-Oshikawa et al., 2005).  Adult mice 
heterozygous for Ube4b show striking axonal dystrophy and degeneration 
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phenotypes, which suggest indeed a role for Ube4b in neuronal integrity 
(Kaneko-Oshikawa et al., 2005).  Ube4b also interacts with and mediates the 
polyubiquitination of ataxin-3, the protein involved in the neurodegenerative 
disease spinocerebellar ataxia 3 (SCA-3) (Matsumo et al., 2004).  In SCA-3, 
ataxin-3 has an expanded polyglutamine repeat, resulting in protein aggregates 
and eventual neuronal death.  Upon overexpression of Ube4b, the degeneration 
phenotype of a Drosophila model of SCA-3 was suppressed (Matsumo et al., 
2004).  This evidence suggests that Ube4b function has a vital role in the 
maintenance of healthy neurons.  In fact, when the N70 portion of Ube4b was 
expressed in dorsal root ganglion (DRG) cultures, transected axons showed a 
slight delay in degeneration, though it was not as strong of a protection as full-
length Wlds (Conforti et al., 2007).   
 Since the N70 Ube4b domain alone was found to confer some protection, 
it was important to find the substrates that bind the N70 domain of Wlds.  Aside 
from ataxin-3, Ube4b also binds to valosin-containing protein (VCP) (Matsumo et 
al., 2004).  More specifically, VCP binds the N-terminal 16 amino acids of Ube4b 
and Wlds (N16) (Laser et al., 2006).  VCP is a member of the AAA+ class of 
ATPases that has been shown to have critical roles in the ubiquitin proteasome 
system (for a review, see Halawani and Latterich, 2006).  VCP also seems to 
play a role in neurodegeneration.  The Drosophila homologue of VCP, Ter94, has 
been shown to be upregulated in late stages of polyglutamine disease models 
(Higashiyama et al., 2002).  Overexpression of Ter94 induces eye degeneration 
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in otherwise wild-type flies, and a knockout of Ter94 suppresses eye 
degeneration in a polyglutamine disease model (Higashiyama et al., 2002).  
Because of its high homology to VCP, TER94 would be predicted to bind Wlds as 
well, shown in chapter 2 of this thesis.  The exact mechanism by which VCP 
interaction with Wlds may lead to protection is unclear, but studies have shown 
that Wlds relocates VCP in the nucleus from a disperse arrangement to distinct 
nuclear foci (Laser et al., 2006).  Also, ubiquitin epitopes accumulate in the foci 
where Wlds and VCP are located (Laser et al., 2006).  Additionally, Wlds lacking 
the N16 portion that binds VCP is unable to protect in vivo (Coleman, personal 
communication), suggesting that the VCP binding event is critical for protection.  
However, the possibility that other protective molecules bind to N16 cannot be 
ruled out.  Since it seems that Ter94 has an active role in promoting 
degeneration, one could imagine that its relocalization in the nucleus may inhibit 
its normal function, thereby inhibiting degeneration.  Other evidence has shown 
that some proteins are activated by mono-ubiquitination and that an E4 enzyme 
(like Ube4b) is responsible for inactivating these proteins by adding a poly-
ubiquitin chain (for a review, see Hoppe, 2005).  Therefore, another model may 
be that the Ube4b domain and VCP act together to bind the proteins normally 
inactivated by ubiquitination in neurodegeneration, but because the Ube4b 
domain is unable to ubiquitinate the substrates, these substrates remain active.   
 
(2) Wlds Nmnat1 Domain and NAD+ Synthesis 
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 The third domain of the Wlds gene encodes the full-length Nmnat1 protein.  
Nmnat1 catalyzes the linking of NMN+ or NaMN+ with ATP to produce NAD+ or 
NaAD+, respectively.  NAD+ is an important energy molecule in the cell, thus one 
proposed hypothesis is that Wlds is simply providing the axon with excess energy 
that prolongs its survival.  There is evidence both supporting and contradicting 
this claim. 
 The Nmnat1 activity in Wlds mice is four times higher than that of wild-type 
mice (Mack et al., 2001).  In DRG cultures, overexpression by transfection of 
Nmnat1 can protect axons against transection and vincristine exposure as well 
as Wlds.  This protection is due to NAD+ synthesis, as inhibiting the enzyme 
activity of Nmnat1 blocks its ability to protect axons (Araki et al., 2004).  
Furthermore, simply adding NAD+ or its precursor NAm can protect DRG 
neurites after transection, although the protection is not as robust as 
overexpressing Nmnat1 (Araki et al., 2004, Wang et al., 2005).  Finally, addition 
of several substrates/enzymes involved in the salvage NAD+ pathway delays 
degeneration in DRG cultures (Sasaki et al., 2006).  However, the steady-state 
NAD+ levels are not altered in the uninjured Wlds mouse (Mack et al., 2001), 
arguing that an increase in overall NAD+ levels is not the mechanism by which 
Wlds protects axons. 
 The in vitro evidence that suggests Nmnat1 alone is responsible for Wlds 
protection is not supported by what is found in vivo.  Besides the fact that NAD+ 
levels are not increased in the uninjured Wlds mice, overexpression of Nmnat1 in 
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vivo (at levels comparable to that found in the Wlds mice) does not confer any 
protection against nerve transection (Conforti et al., 2007).  When DRG neurons 
from these Nmnat1 overexpression mice are cultured and transected, still no 
protection occurs.  Lentiviral delivery of Nmnat1 in vitro offers some protection 
against transection, but the protection is not at the same level as Wlds (Conforti et 
al., 2007).  Unexpectedly, Conforti, et al. found that enzymatically inactive 
Nmnat1 provided the same amount of protection as Nmnat1 with enzymatic 
activity in vitro, arguing that NAD+ synthesis is not required for protection, and 
NAD+ alone added to the DRG culture had no protective effect (2007).  The 
conflicting in vivo and in vitro evidence may be a result of differences in 
expression of Nmnat1, but the results overall call for an extensive in vivo study. 
  
(3) Wlds Gene regulation via NAD+ or an Unknown Mechanism 
To account for the fact that NAD+ levels do not increase in the cell body or 
axon of Wlds-expressing mice, it has been proposed that NAD+ may be acting in 
a more localized manner in the nucleus.  As stated before, Wlds is localized to 
the nucleus, so it follows that perhaps the Nmnat1 domain is functioning to 
increase NAD+ levels in the nucleus.  NAD+ has known nuclear targets that 
affect gene transcription.  Therefore, Wlds may regulate important genes through 
the Nmnat1 domain.  Again, there are studies both supporting and contradicting 
this claim. 
 Further supporting the thought that NAD+ may be exerting its protective 
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effects by regulating genes is the fact that in the experiments where protection 
was seen, exogenous NAD+ had to be added at least 24 hours before 
transection to see a protective effect (Araki et al., 2004, Sasaki et al., 2006).  
Certain NAD+-dependent molecules exist in the nucleus.  One class of molecules 
is the poly-ADP ribose polymerases, PARPs, which are important for DNA 
damage response and repair.  However, when an inhibitor of PARP was added 
to cultured DRG neurons, NAD+ was still able to protect (Araki et al., 2004).  
Another class of NAD+-dependent molecules is the sirtuins, which are protein 
deacetylases that have been implicated in transcriptional regulation during stress 
responses and cell differentiation.  When a SIRT1 inhibitor (sirtinol) was added to 
DRG cultures, exogenous NAD+ was no longer able to protect against nerve 
transection (Araki et al., 2004).  An enhancer of SIRT1, resveratrol, was able to 
protect axons as well as NAD+.  Furthermore, an siRNA directed against SIRT1, 
but not siRNAs directed against the other 6 mammalian sirtuins, blocked NAD+ 
protection of severed axons (Araki et al., 2004).  This suggests that SIRT1, a 
sirtuin that targets histone proteins and transcription factors such as p53, 
forkhead, and NF-κB, may regulate Wlds-mediated protection through Nmnat1 
production of NAD+ in the nucleus.  Wang, et al., however, looked at neurons 
from a SIRT1 knock out mouse, and found no difference in the protective effects 
of Wlds on transected neurons (2005).  Also, they found that neither sirtinol nor 
resveratrol had an effect on Wlds, Nmnat1, or NAD+ protection.  Another lab 
found that resveratrol had no protective effects on DRG cultures (Conforti et al., 
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2007).  These conflicting data once again point to the importance of studying 
claims in vivo.   
 It is entirely possible that Wlds is affecting the transcription of other genes 
through NAD+-independent mechanisms. In fact, some genes have been shown 
to be up or down-regulated in the Wlds mouse that are not known targets of 
sirtuins, though study on one such gene pulled out of a microarray did not show 
neuroprotection (Gillingwater et al., 2006).   
 
(4) Wlds compensates for an endogenous survival signal 
 Since axon degeneration occurs in many instances where axonal 
transport is blocked, not just after transection, it was proposed that a survival 
signal is constantly delivered to a healthy axon that allows the axon to remain 
intact.  Once the delivery of this molecule is compromised, either through 
transection or blockade, the axon will degenerate.  In the case of Wlds, 
something within Wlds is able to compensate for the loss of a survival signal and 
prolong the life of an axon.   
 Gilley and Coleman (2010) treated neurons with cyclohexamide or 
emetine to block protein synthesis and found that the axons showed signs of 
blebbing and fragmentation without affecting the cell body, strengthening the 
hypothesis that after the degradation of a putative survival signal, an axon dies.  
Moreover, Wlds was able to protect neurons treated with cyclohexamide or 
emetine from degeneration, indicating that Wlds is able to compensate for the 
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loss of a survival signal.  Since full-length Nmnat1 is present in Wlds, Gilley and 
Coleman chose to look at Nmnat as a possible survival signal.  3 different 
Nmnats exist in the mouse: Nmnat1 is nuclear, Nmnat2 is cytoplasmic, and 
Nmnat3 is mitochondrial.  Nmnat2 is the only Nmnat highly expressed in neurons 
(Yan et al., 2009).  When neurons are treated with short hairpin RNA (shRNA) for 
either Nmnat1, 2 or 3, only Nmnat2 shRNA reduces the number of healthy 
neurites present, and Wlds is able to inhibit the loss of healthy neurites (Gilley 
and Coleman, 2010).  Finally, when looking at the turnover rates of the Nmnats, it 
is found that Nmnat2 has the shortest half-life, and the timing of its degradation 
coincides with degeneration of an axon and could account for the latent period 
seen after axotomy (Gilley and Coleman, 2010).  Therefore, it was proposed that 
Nmnat2 is an endogenous survival signal delivered to the axon, and that the 
Nmnat1 in Wlds can compensate for loss of Nmnat2 in axons.  This hypothesis 
assumes that the site of Wlds action is outside of the nucleus, as will be 
discussed below.   
While this model is very intriguing, Wallerian degeneration is likely much 
more complicated than just the loss of a single survival signal present in the 
axon.  Many proteins in the axon likely have a similar half-life to that of Nmnat2, 
which needs further investigation.  Also, it is compelling that Nmnat2 can protect 
axons after degeneration (Gilley and Coleman, 2010; Yan et al., 2009).  
However, the protection only occurs when Nmnat2 is expressed at extremely 
high levels in culture, which may result in mislocalization of the protein.  
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Furthermore, there is no in vivo evidence of Nmnat2 protecting severed axons.  
Finally, in chapter 2 and 3 of this thesis, I will show that Nmnat2 is unable to 
protect in vivo in Drosophila 3 or 5 days after axotomy, even at the levels of Gal4 
overexpression.  The lack of protection in Drosophila cannot be due to the short 
half-life of mouse Nmnat2.  Nmnat2, when co-expressed with Wlds in Drosophila, 
is still present in the axon at 5 days after axotomy, whereas in the mouse, 
Nmnat2 still degrades in the presence of Wlds (Gilley and Coleman, 2010).  
These data argue that either there is a different mechanism or survival signal in 
Drosophila, or Nmnat2 is not the whole story in mammals. 
 
Wlds is not restricted to the nucleus 
 Because of the strong nuclear localization, many researchers assumed 
that the nucleus was the site of Wlds action.  However, new insights into Wlds are 
beginning to support a site of action outside of the nucleus.  Beirowski et al. 
found that when Wlds was removed from the nucleus by mutating the nuclear 
localization signal in Nmnat1, the cytoplasmic Wlds protected at a level that was 
higher than normal Wlds (2009).  Synapses and axon structure were intact for 
much longer periods of time, and the cytoplasmic Wlds was even able to protect 
in older mice, which is not observed in normal Wlds.  They also found that this 
mutant Wlds fractionated mostly with mitochondria, providing a new and exciting 
site of action outside of the nucleus.  Around the same time of this study, another 
group found that when Nmnat1 alone was targeted to the cytoplasm, it protected 
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at levels better than Wlds, both in vitro and in vivo (Sasaki et al., 2009).  In vivo 
protection of Nmnat1 in mammals had not been observed until this study.  In 
chapter 2, I will show that mammalian Nmnat1 can protect Drosophila axons, but 
that the protection is never as strong as Wlds.  Perhaps due to the 
overexpression of the Gal4 system, some of the Nmnat1 is localized outside of 
the nucleus, which accounts for the partial protection.  Immunohistochemistry of 
Nmnat1 in Drosophila axons shows that mammalian Nmnat1 is nuclear, 
however, the possibility exists that Nmnat1 is below detection level out in the 
axon.  In fact, in a mammalian fractionation study, Nmnat1 exists in fractions 
other than just the nuclear one (Yahata et al., 2009). 
 Due to the increase in protection when detectable amounts of Wlds or 
Nmnat1 were in the cytoplasm, both the above mentioned studies highlighted the 
fact that although researchers had not yet been able to detect Wlds out in the 
axon with immunohistochemistry, a role for Wlds outside of the nucleus could not 
be excluded.  In fact, Yahata et al. recently published evidence of Wlds 
predominantly in the nuclear and mitochondrial fractions of brain homogenate 
from Wlds mice (2009).  They further fractionated the mitochondria, and found 
Wlds in the inner membrane and matrix.  Interestingly, they found that Nmnat3 
was also localized to the same suborganellar space as Wlds.  When Nmnat3 was 
overexpressed in vivo, it protected as well as Wlds.  This was the first 
endogenous Nmnat that when overexpressed in vivo protects axons.  All of the 
mounting evidence points to a role for Wlds outside of the nucleus, and most 
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likely in the mitochondria.   
 
Mitochondria and calcium 
 The discovery of Wlds in the mitochondria begs the question of whether 
the site of Wlds action is in the mitochondria and, if so, how Wlds could act in the 
mitochondria to prevent axon degeneration.  But first, why are mitochondria 
important to the axon?  The answer to this question lies in the ability of 
mitochondria to buffer calcium, a major signaling molecule in cells that can 
quickly lead to cell death if the amount of calcium becomes too high.  It was first 
reported by Vasington and Murphy as well as DeLuca and Engstrom in 1961 that 
isolated mitochondria were able to uptake large amounts of calcium (reviewed in 
Carafoli, 2010).  The calcium is taken up into mitochondria through what has 
been called the mitochondrial calcium uniporter (MCU), a highly selective ion 
channel made up of unknown proteins.  Recent papers have proposed that 
LetM1 and MICU1 are necessary for mitochondrial calcium uptake and suggest 
either protein may be a part of the uniporter (Kirchok et al., 2004; Jiang et al., 
2009; Perocchi et al, 2010).  The low affinity of the MCU for calcium, however, 
lead to the belief that mitochondria were probably not a calcium sink in vivo.  This 
viewpoint was challenged upon the discovery of localized pools of high amounts 
of calcium that could compensate for the low affinity of the MCU for calcium 
(Gunter et al., 1998).  Also, advances in fluorescence technology and the ability 
to compartmentalize fluorescent calcium sensors have confirmed that 
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mitochondria do, indeed, uptake large amounts of calcium in vivo (Celsi et al., 
2009).   
 Although the endoplasmic reticulum can also uptake calcium, 
mitochondria are thought to be the main calcium buffers, as they are highly 
motile and can respond to high amounts of calcium (Carafoli, 2010).  Calcium 
uptake by mitochondria depends on the mitochondrial membrane potential; 
mitochondria cannot clear calcium from the cytoplasm if the membrane potential 
has collapsed (Babcock et al., 1997).  Once inside the mitochondria, calcium can 
activate three key metabolic enzymes that lead to an increase in ATP production 
(Celsi et al., 2009).  The calcium, in the presence of phosphate, is then 
precipitated into an insoluble phosphate salt, which serves to quench and buffer 
the calcium signal (Carafoli, 2010).   
 
Mitochondria movement is determined by Ca2+ 
 We now know that mitochondria are able to uptake large amounts of 
calcium in the cell and it has been observed that mitochondria accumulate at 
sites of increased calcium (MacAskill et al., 2009).  How do they reach local 
pools of calcium and when they get there, how do they sense the change in 
calcium?  The answer to both of these questions is in part, mitochondria Rho-
GTPase (Miro).  Miro is an atypical Rho GTPase, which is bound to the outer 
mitochondrial membrane.  In miro mutants, Drosophila larvae exhibit locomotor 
deficits, the neuromuscular junction shows abnormal organization, and the 
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mitochondria are clustered in the cell body with few, if any, in the axon (Guo et 
al., 2005).  Further studies have shown that miro is also involved in mitochondrial 
movement in mammalian cells, as knockdown results in a reduction of 
mitochondria movement (Saotome et al., 2008; Wang and Schwarz, 2009; 
MacAskill et al., 2009).  Overexpression of Miro in mammalian cells results in an 
increase in mitochondria movement (Saotome et al., 2008), but in Drosophila 
neurons, overexpression results in a dominant-negative phenotype of less 
mitochondrial movement (Russo et al., 2009).  It was also noted that a 
heterozygous null of miro in Drosophila motorneurons results in a decrease in 
mitochondria movement, so it seems Drosophila motorneurons are highly 
sensitive to Miro levels (Russo et al., 2009).  Miro’s role in the movement of 
mitochondria consists of two parts: (1) sensing calcium, and (2) binding adaptor 
molecules and kinesin. 
 Miro contains 2 EF hand motifs, which are well-characterized calcium-
binding domains.  When a calcium-mobilizing hormone is added to cells, 
mitochondria movement is inhibited (Saotome et al., 2008).  If the EF hands are 
mutated, the mitochondria no longer stop in the presence of calcium (Saotome et 
al., 2008).  This finding has been repeated by two other groups with different 
methods to raise intracellular calcium levels (MacAskill et al., 2009; Wang and 
Schwarz, 2009).  Mammalian cells that express a constitutively active version of 
Miro or overexpress wild-type Miro are more sensitive to calcium, consistent with 
Miro being a calcium sensor (Saotome et al., 2008). 
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 The second function of Miro is to bind kinesins and adaptors to move the 
mitochondria along the microtubules, and is thought to be calcium-sensitive as 
well, providing a mechanism for how mitochondria can stop in the presence of 
calcium.  Miro binds Milton, an adaptor molecule, in a calcium-independent 
manner (Wang and Schwarz, 2009; MacAskill et al., 2009).  Mutations of milton 
show a very similar phenotype to those of miro, with a greatly reduced number of 
mitochondria present in axons (Glater et al., 2006).  After Miro binds Milton, 
Milton then binds kinesin heavy chain in a calcium-independent manner, and 
promotes kinesin localization on mitochondria (Glater et al., 2006).  Again, 
mutants of the kinesin heavy chain, KIF5C, result in a similar phenotype to that of 
miro and milton (Pilling et al., 2006).  The involvement of calcium is less clear-
cut.  There are two conflicting results.  Wang and Schwarz report that Miro can 
actually bind the motor domain of kinesin itself in the presence of only high 
amounts of calcium (2009).  The thought is this direct binding of Miro to KIF5C 
without Milton causes the kinesin to fall off the microtubule track, in effect 
stopping the mitochondria.  The MacAskill et al. group similarly reported that Miro 
can directly bind kinesin, however, this interaction occurred in low calcium 
environments (2009).  Upon calcium binding to Miro in higher calcium 
environments, Miro dissociated from kinesin, giving the same effect of 
mitochondria stopping.  Whichever is the mechanism, it is clear that mitochondria 
require Miro for movement, and the calcium-sensing EF domains to localize the 
mitochondria to areas of high calcium, which are in need of calcium buffering and 
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energy from the mitochondria. 
 
Ca2+ dysregulation and cell death 
The ability of mitochondria to respond to and buffer large amounts of 
calcium is incredibly important to the cell.  When mitochondria become 
overloaded with calcium, the mitochondrial permeability transition pore (PTP) can 
open leading to apoptosis (Celsi et al., 2009).  The calcium overload leads to a 
collapse in mitochondria membrane potential, allowing the PTP to open and 
release toxic signals.  In neurons, calcium entry into the cell occurs during 
activity, and it is known that too much activity can lead to excitotoxic death, a 
mechanism known to involve calcium overload in mitochondria (Celsi et al., 
2009).  Interestingly, treating cells with taurine increases the amount of calcium 
that mitochondria can sequester in the presence of glutamate, an excitatory 
neurotransmitter.  This treatment of taurine can actually weakly protect neurons 
from excitotoxicity, indicating that the ability of mitochondria to uptake large 
amounts of calcium is critical to the health of the neuron (Idrissi et al., 2008). 
To put this in the context of Wallerian degeneration, two in vitro studies, 
and one in vivo study have shown the importance of calcium signaling after injury 
in causing degeneration.  Ziv and Spira, and George et al. both reported the 
presence of high amounts of calcium in an axon after axotomy (1995).  Addition 
of EGTA (ethylene glycol tetraacetic acid), a calcium chelator, to the media 
prevented axon degeneration after axotomy for one week, whereas wild-type 
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axons are degenerated in 48-60 hours (George et al., 1995).  George et al. also 
found that if the extracellular calcium was below 200µm, the axon would not 
degenerate, indicating that extracellular calcium is an initiating factor in axon 
degeneration.  Also, when a calcium ionophore was added to the media, 
spontaneous degeneration occurred, axon degeneration after axotomy occurred 
more quickly, and both effects were blocked with the addition of EGTA (George 
et al., 1995).  Recently, these results were duplicated in an in vivo model 
(Knoferle et al., 2010).  Calcium fluorescence was observed in a rat optic nerve 
in vivo after crush.  Calcium levels increased rapidly within 30 seconds after 
crush, and the signal slowly declined.  The increase in calcium was prevented 
with calcium channel blockers, indicating again that the calcium that enters the 
axon is extracellular.  Upon the addition of calcium inhibitors, the axonal integrity 
remained intact, akin to uncrushed nerved, and reciprocally with the addition of 
calcium ionophores, axonal integrity declined at a rate faster than wild-type crush 
(Knoferle et al., 2010). 
Although it still has yet to be confirmed that calcium overload in 
mitochondria after axotomy is what initiates degeneration, the data available 
suggest such a model.  Therefore, one could imagine that if mitochondrial 
calcium buffering capacity were increased, perhaps axon degeneration would not 
occur.  Since Wlds is localized in the mitochondria, it is perfectly poised to affect 
the calcium buffering capacity, a model which will be discussed in chapter 3 of 
my thesis. 
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The Drosophila Olfactory System and Wallerian Degeneration 
The Drosophila olfactory system is highly characterized, and is a great 
model system for Wallerian degeneration.  Odorant receptors (ORs) are encoded 
by 57 genes and each olfactory neuron expresses one or two odorant receptors 
(Vosshall et al., 2000).  Neurons expressing a specific OR converge on one or 
two spatially distinct glomeruli in the antennal lobe (Figure 1-2) (Vosshall et al., 
2000).  The location of the cell bodies in the antennal segments or maxillary 
palps and the location of their respective glomeruli are replicable from animal to 
animal.  Thus, researchers have been able to construct a map of the Drosophila 
olfactory system using OR promoters expressing Gal4 and a UAS-GFP (green 
fluorescent protein) (Vosshall et al., 2000, Cuoto et al., 2005). The OR promoter-
Gal4 lines are extremely useful to the lab, as we can express different domains 
of Wlds under the UAS promoter in a specific, predictable subset of neurons.  We 
can also express GFP in the same subset of neurons to visualize the axons 
before and after injury.  This will enable us to be able to count numbers of 
remaining intact axons after injury is induced. 
To confirm that Wallerian degeneration occurs in Drosophila axons, we 
labeled a subset of olfactory receptor neurons with GFP, surgically ablated the 
third antennal segment, and dissected the brain at various time points to view the 
axons.  At about five hours post-ablation, the axons began to fragment, and by 
day five, the axons were mostly cleared (Figure 1-3) (MacDonald et al., 2006).  
A	   B	   C	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This is consistent with observations of Wallerian degeneration in mammals; there 
is a short latent period after axotomy after which axons undergo rapid 
fragmentation.   Since axon degeneration was very similar to what has been 
observed in mammals, we decided to test if Wlds could suppress axon 
degeneration in Drosophila.   
Wlds was driven in a subset of ORNs with the Gal4-UAS system.  In Wlds-
expressing flies, axons were still present and unfragmented at day five, the time 
point in which wild-type axons were mostly gone (Figure 1-4) (MacDonald, et al., 
2006).  The Wlds-protected axons were present out to 50 days post-ablation, 
showing a similar and even more robust protection than in mammals, thereby 
validating the use of the Drosophila model in studying mechanisms of Wlds.   
 
Significance of the work in this thesis 
Although little is known about axon degeneration, the discovery of the 
Wlds mouse supports the notion that axon degeneration is an active process that 
is very similar in a wide range of diseases, such as Parkinson’s, progressive 
motor neuronopathy, and multiple sclerosis.  In order to better understand 
disease and open the doors to therapy options, it is imperative to study the 
molecular mechanisms of Wlds and axon degeneration.  With our lab’s 
development of a novel method to study axon degeneration after acute nerve 
transection in Drosophila, along with the many genetic tools available for this 
organism, we are poised to make advances in the molecular understanding of 
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axon degeneration and Wlds-mediated protection. 
In the second chapter of my thesis, I outline a detailed structure-function 
analysis of Wlds.  I define the minimal domains of Wlds necessary and sufficient 
for axon protection in Drosophila, which are N16 fused to Nmnat1.  I also find 
that VCP/TER94 is essential for full protection of axons.  Finally, I test if other 
mammalian Nmnats can protect axons, and find that Nmnat1 has an intermediate 
level of protection, Nmnat2 cannot protect, and Nmnat3 can protect as well as 
Wlds 5 days after axotomy. 
In the third chapter of my thesis, I extend the finding that Nmnat3 can 
protect as well as Wlds out to 50 days post axotomy and find no differences 
between the two proteins in the level of axon protection.  Because of their 
protective function and mitochondrial localization, I explore the differences in 
Wlds- or Nmnat3-expressing mitochondria.  I find that when either of these 
strongly neuroprotective molecules are present, mitochondria motility is 
increased.  Upon suppressing this increase in movement with Miro heterozygous 
mutants or Miro overexpression, I find that I can suppress Wlds protective ability, 
indicating that the increase in mitochondrial motility is necessary for protection.  
Finally, I find that after injury, highly neuroprotective molecules strongly suppress 
calcium increase in the axon.  Both the increase in motility of mitochondria and 
the decrease in injury-induced calcium are the first biological changes 
demonstrated in a Wlds-expressing neuron. 
In the fourth chapter of my thesis, I describe a forward genetic screen 
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taken on by many students and technicians in the laboratory to try to uncover 
genes involved in axon degeneration.  Wlds, while a great tool for studying 
degeneration, still does not answer whether axon degeneration is an active 
process because of its gain-of-function nature.  In the screen, we hope to 
definitively demonstrate that axon degeneration is an active process, and in this 
chapter I will describe one such mutant. 
In conclusion, my work has uncovered a model by which Wlds functions 
through mitochondria to increase calcium buffering capacity, thereby rescuing 
axons from calcium-induced death.  Although the action of Wlds does not point to 
the actual mechanism or pathway of axon degeneration, the forward genetic 
screen we have conducted does.  I have also been instrumental in pushing 
forward the screen to uncover axon degeneration genes, and have found at least 
one likely mitochondrial gene to definitively show axon degeneration is an active 
process.  Thus, this work highlights the importance of mitochondria to the axon 
during degeneration, and future studies should focus on the mitochondria to find 
the axonal death pathway. 
	   25	  
 
 
Fig 1-1 
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Figure 1-1 (Conforti, et al. 2000).  Schematic diagram of the Wlds locus (top) 
and the triplication event that occurred (bottom) in the Wlds mouse.  Ufd2 
(Ube4b) fused to D4Cole1e (Nmnat1) in the triplication, but both full-length 
normal genes are still present.  Rbp7 was triplicated in full, resulting in an 
overexpression. 
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Fig 1-2 
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Figure 1-2.  The Drosophila Olfactory system.  (A) 2 pairs of sensory organs 
exist in the adult fly: the antennae (arrowhead) and maxillary palps (arrow).  (B) 
Sagittal diagram of the adult fly head.  Antennal nerves (an) or maxillary nerves 
(mn) project from the exterior structures and converge on spatially distinct 
glomeruli in the antennal lobe.  (C) Frontal view of the antennae and antennal 
lobes.  The projection pattern of neurons expressing the same olfactory receptor 
projects both ipsa- and contralaterally.  The glomeruli are connected by the 
antennal lobe commissure (alc). 
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Fig 1-3 
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Figure 1-3.  Wallerian degeneration occurs in Drosophila (MacDonald et al., 
2006).  (A) Axons are fragmented 1 day post-ablation and mostly cleared by day 
5 post-ablation.  OR-22a axons are labeled with GFP (UAS-mcd8::GFP/+; 
OR22aGal4/+).  (B) Quantification of axon clearance.  3 days post-injury no 
axonal fibers are detected, and GFP intensity decreases post-ablation. 
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Fig 1-4 
	   32	  
Figure 1-4.  Wlds can protect severed Drosophila axons (MacDonald et al., 
2006).  (A) Control flies 5 days post-ablation have very little GFP-positive axonal 
material remaining in the antennal lobe (UAS-mcd8::GFP/+; OR22aGal4/+). (B) 
Wlds-expressing flies have intact axons 5 days post-ablation, (C) axons are still 
seen at day 20, and (D) GFP-positive material is still present at 50 days post-
ablation (UAS-mcd8::GFP/+; OR22aGal4/UAS-Wlds).  (E) Quantification of 
axonal presence in the antennal lobes (top) and GFP intensity in the glomeruli 
(bottom).  Wlds-expressing flies show 100% axon presence out to 30 days post 
ablation and show a very minimal decline in GFP intensity out to 50 days post-
ablation.  This is in sharp contrast to wild-type where no axons are present 5 
days post-ablation, and the glomeruli GFP intensity is near zero at 5 days post-
ablation. 
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Chapter II: 
Wlds requires Nmnat1 enzymatic activity and N16-VCP 
interactions to suppress Wallerian degeneration 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The following work is reprinted from the Journal of Cell Biology article of the 
same name published as: 
Avery, M.A., Sheehan, A.E., Kerr, K.S., Wang, J., and Freeman, M.R.  J Cell Bio, 
23 February 2009: Vol. 184. No. 4, pp 501-513.
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Abstract 
Slow Wallerian degeneration (WldS) encodes a chimeric Ube4b/nicotinamide 
mononucleotide adenylyl transferase 1 (Nmnat1) fusion protein that potently 
suppresses Wallerian degeneration, but the mechanistic action of WldS remains 
controversial. In this study, we characterize WldS-mediated axon protection in 
vivo using Drosophila melanogaster. We show that Nmnat1 can protect severed 
axons from autodestruction but at levels significantly lower than WldS, and 
enzyme- dead versions of Nmnat1 and WldS exhibit severely reduced axon-
protective function. Interestingly, a 16–amino acid N-terminal domain of WldS 
(termed N16) accounts for the differences in axon-sparing activity between WldS 
and Nmnat1, and N16-dependent enhancement of Nmnat1-protective activity in 
Wld requires the N16-binding protein valosin-containing protein (VCP)/TER94. 
Thus, WldS-mediated suppression of Wallerian degeneration results from VCP–
N16 interactions and Nmnat1 activity converging in vivo. Surprisingly, mouse 
Nmnat3, a mitochondrial Nmnat enzyme that localizes to the cytoplasm in 
Drosophila cells, protects severed axons at levels indistinguishable from WldS. 
Thus, nuclear Nmnat activity does not appear to be essential for WldS-like axon 
protection.   
	   35	  
Introduction 
Axons represent the key cellular outgrowth that permits connectivity between 
distant neurons or neurons and their non- neuronal targets (e.g., muscles). 
Axons can be extremely long, traversing great distances, and in most neurons, 
the axonal compartment composes the majority of the cellular volume. Because 
of the significant length and volume of the axon, its stabilization represents a 
major and ongoing challenge for neuronal cell types.   
Wallerian degeneration serves as an extremely useful context in which to 
study molecular and cellular mechanisms that mediate axon integrity. Acute 
axotomy induces large-scale axon degeneration after a defined latent phase that 
bears striking resemblance to axon degeneration during developmental pruning 
(Luo and O’Leary, 2005) and in neurodegenerative disease (Coleman, 2005). 
Wallerian degeneration was long thought to represent a passive wasting away of 
the distal portion of the severed axons (Waller, 1850) caused by a lack of 
nutrients from the cell body, but a revolution in our understanding of axon biology 
came with the discovery of the spontaneous C57BL/slow Wallerian degeneration 
(WldS) mutant mouse. Amazingly, severed WldS mutant axons survived for 
weeks after axotomy (Lunn et al., 1989; Glass et al., 1993). This observation 
indicated that the WldS mutation somehow suppressed axon autodestruction and 
suggested for the first time that Wallerian degeneration might be an active 
process of axon autodestruction akin to apoptotic cell death (Coleman and Perry, 
2002; Raff et al., 2002). Subsequent analysis of the WldS mutant has provided 
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intriguing insights into the molecular relationships between axon degeneration in 
developmental, injury, and disease contexts. For example, the WldS mutation can 
suppress axon degeneration induced by chemical toxicity (Wang et al., 2001), 
nerve crush (Beirowski et al., 2005), and mouse models of neurodegenerative 
disease (Ferri et al., 2003; Coleman, 2005), suggesting that the underlying 
programs that drive axon autodestruction in these distinct degenerative contexts 
share common molecular features. However, WldS does not suppress axon 
degeneration during developmental axon pruning in Drosophila melanogaster or 
mammals (Hoopfer et al., 2006), arguing that WldS-independent molecular 
programs drive axon degeneration in developmental settings. 
The WldS mutation was recently found to result in the fusion of two genes, 
the NAD+ biosynthetic molecule nicotinamide mononucleotide adenylyl 
transferase 1 (nmnat1) and Ube4b, an E4 ubiquitin ligase (Conforti et al., 2000; 
Mack et al., 2001). The protein encoded by this locus, termed WldS (Fig. 2-1 A), 
is composed of the N-terminal 70 amino acids of Ube4b (termed N70), a unique 
18–amino acid domain generated during the gene fusion event (termed W18), 
and the full-length sequence of mouse nmnat1. Expression of this protein in 
mouse neurons fully recapitulates the WldS mutant phenotype (Mack et al., 2001) 
and can even protect severed axons from autodestruction in distant species like 
Drosophila (Hoopfer et al., 2006; MacDonald et al., 2006). 
Three main models have been proposed to explain WldS-mediated axon 
protection. The first argues that Ube4b may have a dominant-negative effect on 
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the ubiquitin proteasome (UPS) pathway. Although the N70 portion of Ube4b 
does not have ubiquitination activity on its own, it contains domains capable of 
binding Ube4b substrates, implying that N70 may bind key substrates in vivo, fail 
to target them for degradation, and, in turn, somehow stabilize severed axons. 
Consistent with this model, the UPS pathway has been shown to be essential in 
promoting axon autodestruction during Wallerian degeneration (Zhai et al., 2003) 
and developmental axon pruning (Watts et al., 2003), but a direct functional link 
between WldS and the UPS pathway is lacking. A second hypothesis is that 
Nmnat1, a NAD+ biosynthetic enzyme, acts to produce excess NAD+ in the axon 
after injury and thereby stabilize the axon. Two groups reported that application 
of NAD+ or its precursors to neuronal cultures partially suppressed axon 
degeneration in vitro (Araki et al., 2004; Wang et al., 2005); however, a third 
study found no enhancement of survival of severed axons from primary neuronal 
cultures with NAD+ application (Conforti et al., 2007). Moreover, transgenic mice 
expressing Nmnat1 in neurons failed to phenocopy WldS (Conforti et al., 2007). 
Finally, a third model proposes that Nmnat1 acts in the nucleus before injury 
through Sirt1, a member of the sirtuin family of NAD+-binding histone 
deacetylases, to change patterns of neuronal gene expression before injury, 
which protects severed axons after axotomy (Araki et al., 2004). Araki et al. 
(2004) provided in vitro data in support of this model showing that siRNAs 
directed toward sirt1 could partially suppress the neuroprotective effects of bath-
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applied NAD+; however, a null allele of sirt1 failed to suppress the ability of WldS 
to protect severed axons in vivo (Wang et al., 2005). 
The aforementioned models remain open possibilities but have not been 
tested incisively in vivo. In this study, we explore the in vivo mechanistic action of 
WldS in Drosophila. We find that WldS-mediated protection requires two activities: 
Nmnat1 enzymatic function and the N-terminal 16 amino acids of N70 (termed 
N16). We show that N16 associates with TER94, the fly orthologue of the mouse 
N16-binding molecule valosin-containing protein (VCP; Laser et al., 2006), and 
that VCP is essential for WldS-like levels of axon protection. Thus, the converging 
activity of domains derived from both Ube4b and Nmnat1 are essential for WldS-
like levels of axon protection in vivo. Surprisingly, we find that Nmnat3, a mouse 
mitochondrial Nmnat that localizes throughout the cytoplasm in Drosophila cells 
(but not to the nucleus), can protect severed axons as well as WldS. Thus, 
nuclear localization of Nmnat activity is not essential for robust axon protection, 
and these data raise the intriguing possibility that N16–VCP/Ter94 interactions 
may function to relocalize Nmnat1 outside of the nucleus, perhaps to 
mitochondria, where it exerts its neuroprotective effects. 
 
Results 
Constructs generated for in vivo functional dissection of WldS  
The adult Drosophila olfactory system offers an excellent opportunity to 
study Wallerian degeneration and WldS function in a well-controlled in vivo 
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setting: odorant receptor (OR)–Gal4 driver lines can be used to reproducibly 
label specific subsets of axons with membrane-tethered GFP (mCD8-GFP); 
nonlethal surgical ablation of antennae or maxillary palps induces Wallerian 
degeneration of olfactory receptor neuron (ORN) axons; severed axon 
degeneration can be monitored in the intact brain for months after injury; and 
neuroprotective molecules like WldS can be expressed in these axons at 
standardized levels to quantitatively compare neuroprotective activity 
(MacDonald et al., 2006). In this study, we use this system to define the 
functional domains in WldS that are essential for protection of severed axons in 
vivo. 
We constructed several transgenic Drosophila lines carrying variants of 
the WldS molecule (Fig. 2-1 A): (a) upstream activating sequence (UAS)–
nmnat1, full-length mouse nmnat1; (b) UAS-nmnat1dead, full-length mouse 
nmnat1 with an H24A substitution, which has been previously shown to allow 
folding of Nmnat and binding of its substrate but largely to abolish substrate 
conversion to NAD+ (Saridakis et al., 2001); (c) UAS- WldS-ΔN16, WldS with a 
deletion of the first 16 amino acids (termed N16), which was previously shown to 
bind VCP (Laser et al., 2006); (d) UAS-N16::nmnat1, a fusion of N16 to full- 
length Nmnat1; and (e) UAS-WldS-dead, full-length WldS with an H24A substitution 
in the Nmnat1 portion of the molecule. To determine the subcellular localization 
of WldS and the aforementioned variants, we also generated C-terminally Myc 
epitope–tagged versions of WldS, WldS-dead, and Nmnat1 (UAS- WldS::Myc, 
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UAS-WldS-dead::Myc, and UAS-Nmnat1::Myc). When expressed in Drosophila, 
antennal lobe projection neurons in the central brain of all of these molecules 
localized exclusively to the nucleus (Fig. 2-1, B–G), indicating that the H24A 
mutations that abolish NAD+ biosynthetic activity do not alter the subcellular 
localization of WldS. We further note the conspicuous absence of WldS+ nuclear 
puncta in Drosophila neurons (Fig. 2-1, B and C) and S2 cells (see Fig. 2-5, A 
and B) that have been observed when WldS is expressed in mammalian cell lines 
(Laser et al., 2006). Thus, WldS localizes to the nucleus in Drosophila neurons, 
and these data argue that the presence of WldS+ nuclear puncta is not essential 
for WldS to exert its neuroprotective effects. 
Multiple transgenic lines were established for each construct, and at least 
three lines bearing independently isolated transgene insertions were assayed for 
protein expression levels (Fig. 2-2) and functional protection (see following 
section). The efficiency of protein expression from each transgene was assayed 
by crossing individual UAS lines to the panneuronal driver elav-Gal4, preparing 
protein extracts from head, and assaying protein levels with α-Nmnat1 antibodies 
on Western blots. All WldS variants carry full-length Nmnat1, and thus, this 
antibody should recognize each with equal affinity. In some cases, each of the 
three transgenic lines for a given construct expressed very similar levels of 
protein (e.g., N16::Nmnat1 and WldS-ΔN16); for others, the total expression level of 
each protein varied among transgenic lines (e.g., WldS, Nmnat1, Nmnat1dead, and 
WldS-dead). Despite this fact, the in vivo axon-protective function of each molecule 
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was in most cases strikingly similar among transgenic lines carrying different 
insertions of the same transgene (see following section). 
 
Wallerian degeneration is potently suppressed by WldS and partially 
blocked by Nmnat1, and axonal protection requires Nmnat1 enzymatic 
activity 
 To compare the protective effects of the aforementioned transgenes, we 
crossed each to the ORN-specific driver OR22a-Gal4, severed ORN axons, and 
determined the number of remaining intact axonal fibers present at 5, 10, 15, 20, 
and 30 d after injury (Fig. 2-S1). Each neuroprotective molecule showed a 
unique pattern of protection, but this was indistinguishable among the other 
transgenic lines carrying the same transgene (Fig. 2-S2), and therefore, axon 
protection data were pooled for each transgene (Fig. 2-3). 
We first asked whether Nmnat1 could protect severed axons in vivo at a 
level similar to WldS and whether Nmnat1 enzymatic activity was essential for 
axonal protection. Previously, we reported that mouse WldS could robustly 
suppress Wallerian degeneration in Drosophila for at least 20 d after injury 
(MacDonald et al., 2006). We have now confirmed and extended this finding to 
30 d after injury, with the majority (77%) of WldS-expressing axons remaining 
intact for this period (Fig. 2-3). Interestingly, we found that expression of mouse 
Nmnat1 in ORNs also partially suppressed Wallerian degeneration; however, 
Nmnat1 was significantly less effective than WldS at protecting severed axons. 
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For example, the majority of severed axons in animals expressing WldS remained 
intact even 30 d after injury (77%), whereas a minority of axons expressing 
Nmnat1 (32%) remained intact at this time point. Thus, Nmnat1 is indeed a 
neuroprotective molecule in vivo and likely represents an important component of 
the severed axon-protecting activity of WldS. However, the fact that Nmnat1 
provided significantly reduced protection of severed axons compared with WldS 
argues that N70 and/or W18 enhances the neuroprotective nature of Nmnat1 in 
important ways to provide WldS-like levels of axon protection. 
Next, we assayed the ability of enzyme-dead variants of WldS and Nmnat1 
to protect severed axons. Strikingly, blocking the enzymatic activity of Nmnat1 
with an H24A mutation almost completely eliminated the ability of Nmnat1 to 
protect severed axons. In Nmnat1dead-expressing animals, 100% of all axons had 
undergone Wallerian degeneration within 10 d after injury (Fig. 2-3). Thus, 
Nmnat1-dependent axon protection requires the NAD+ biosynthetic activity of 
Nmnat1. Consistent with a role for Nmnat1 enzymatic activity in promoting WldS-
dependent axon protection, we found that WldS-dead also exhibited strongly 
reduced neuroprotection: in WldS-dead-expressing animals, 92% of axons had 
degenerated within 15 d after injury (Fig. 2-3). Interestingly, and in contrast to 
Nmnat1dead, WldS-dead exhibited intermediate levels of protection until 10 d after 
injury, indicating that WldS-dead retains a moderate level of axon-sparing activity 
despite having reduced Nmnat1 enzymatic activity. These data provide further 
strong evidence that N70 or W18 domains of WldS are important for WldS-
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dependent protection of severed axons and indicate that Nmnat1 enzymatic 
activity is essential for sustained WldS-dependent protection of axons. 
The N16 domain of WldS is essential for maximal axon protection and accounts 
for differences in neuroprotection observed between WldS and Nmnat1. 
Which portion of N70 or W18 is responsible for the increased 
neuroprotection of WldS relative to that observed with Nmnat1? Previous 
biochemical experiments identified N16 as a binding site for association of WldS 
with VCP (Laser et al., 2006). We sought to determine the functional 
requirements for the N16 domain in WldS-mediated protection of severed axons 
in vivo. Therefore, we generated two transgenic constructs, WldS-ΔN16 (harboring a 
specific deletion of the N16 domain) and N16::Nmnat1 (in which only the N16 
domain is directly fused to the N terminus of Nmnat1; Fig. 2-1 A) and assayed 
axon-protective effects. In striking contrast to the protection observed with WldS, 
WldS-ΔN16 provided significantly reduced protection of severed axons, with 25% 
and 35% of axons degenerating by day 10 and day 20 after injury, respectively 
(Fig. 2-4). WldS-ΔN16- mediated protection was indistinguishable from that afforded 
by Nmnat1, suggesting that N16 is the key domain responsible for the increased 
protection we observed in axons expressing WldS compared with Nmnat1. 
Reciprocally, N16::Nmnat1 expression in axons provided significantly increased 
protection of severed axons relative to Nmnat1 alone, with >90% of axons 
surviving as long as 20 d after injury (Fig. 2-4). Therefore, N16::Nmnat1– 
mediated protection of severed axons was indistinguishable from the protection 
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provided by WldS. In summary, we find that N16 is essential for WldS-like 
neuroprotective activity and is sufficient when tethered to Nmnat1 to provide 
WldS-like levels of severed axon protection in vivo. Together, the aforementioned 
data indicate that WldS-mediated axon protection results from two synergizing 
activities: (1) Nmnat1 enzymatic activity and (2) N16-dependent protein–protein 
interactions. 
 
VCP/TER94 binds to N16 and is essential for WldS-like neuroprotection  
The only protein known to physically interact with WldS is VCP, and it does 
so through the N16 domain (Laser et al., 2006), but its role in WldS-mediated 
axon protection remains unclear. To determine whether Drosophila VCP, known 
as TER94 (Pinter et al., 1998), associates with mouse WldS, we transfected 
Drosophila S2 cells with WldS::Myc and performed coimmunoprecipitation 
experiments with α-Myc antibodies. We found that WldS::Myc was stably 
expressed in Drosophila S2 cells and localized primarily to the nucleus (Fig. 2-5, 
A and B). Two isoforms of TER94 are present in Drosophila, one of 50 kD 
(isoform A) and a second of 97 kD (isoform B). We found that S2 cells normally 
express the 50-kD isoform and lower levels of the 97-kD isoform. 
Immunoprecipitations with α-Myc antibodies from WldS::Myc–transfected S2 cells 
led to robust co- purification of the 97-kD isoform (which is >80% identical to 
mouse VCP; Fig. 2-5 C), indicating that WldS::Myc can associate with TER94. 
Whether WldS::Myc associates with the 50-kD isoform of TER94 remains unclear 
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because this protein runs at the same size as the mouse IgG heavy chain used 
for WldS::Myc pull-downs. Thus, TER94, like VCP in mammals, can physically 
associate with WldS in Drosophila. 
Next, we sought to determine whether loss of TER94 function could 
suppress the ability of WldS to protect severed axons. Because deletion of N16 
from WldS suppresses the axon-protective function of WldS to levels equivalent to 
Nmnat1 (Fig. 2-4), we predicted that blocking TER94 function in WldS-expressing 
neurons should phenocopy the protective effects of Nmnat1 and WldS-ΔN16. We 
first assayed whether null alleles of TER94 could dominantly suppress the ability 
of WldS to protect severed axons, but WldS-expressing animals lacking a single 
copy of TER94 showed the normally high levels of axon protection we observe in 
WldS-expressing axons (unpublished data). We were unable to assay TER94 
function in WldS-mediated axon protection in a null TER94 background because 
animals homozygous for strong loss of function alleles of TER94 are 
homozygous lethal (Ruden et al., 2000). Therefore, we turned to RNAi methods 
to knock down TER94 function specifically in WldS-expressing axons. Strikingly, 
we found that knocking down TER94 in WldS-expressing axons with UAS-
TER94RNAi suppressed the axon-protective function of WldS to levels 
indistinguishable from Nmnat1 and WldS-ΔN16 (Fig. 2-5 D). Uninjured age-matched 
controls for WldS/TER94RNAi and TER94RNAi animals were indistinguishable from 
day 0 controls, and thus, the axon loss observed in WldS/TER94RNAi animals was 
dependent on axotomy. We note that RNAi for TER94 alone did result in a slight 
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but significant reduction in the number of axons present in uninjured animals in 
the absence of WldS (Fig. 2-5 D), suggesting that TER94RNAi can induce low level 
axon degeneration. However, the vast majority of axons in these animals were 
intact before injury and in age-matched controls, indicating that TER94RNAi 
treatment does not cause widespread degeneration of axons on its own. In 
summary, we conclude that TER94 is autonomously required in WldS-expressing 
neurons in vivo for WldS to maximally protect severed axons from 
autodestruction. Furthermore, we propose that the key neuroprotective portion of 
the N70/W18 domain of WldS is N16 and that its neuroprotective effects are 
mediated by a TER94/VCP-dependent mechanism. 
A major cellular role for TER94/VCP is targeting proteins for refolding, or 
destruction as part of the UPS degradation pathway. TER94/VCP sits at a pivotal 
point in the cascade, having the ability to direct refolding or degradation of 
substrates based on its binding partners. When associated with ubiquitinated 
proteins, VCP can either bind Npl4 and Ufd2 and target proteins for proteasomal 
degradation or bind Ufd1 and Plap and release refolded proteins into the 
cytoplasm (for review see Halawani and Latterich, 2006). In an attempt to identify 
additional molecules that interact with TER94/VCP to modulate axon 
autodestruction or WldS-mediated neuroprotection, we assayed the requirements 
of the following Drosophila genes in Wallerian degeneration and WldS function: 
CG4673, encoding the Drosophila orthologue of npl4; ufd2; ufd1-like; and plap, 
encoding the Drosophila orthologue of Ufd3. For each molecule, we used UAS-
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regulated RNAi constructs to knock down their function in neurons and assayed 
the ability of these molecules to (a) induce spontaneous axon degeneration, (b) 
suppress axon autodestruction 15 d after injury, and (c) suppress the ability of 
WldS to protect severed axons. We found that knockdown of each of these genes 
failed to dramatically suppress normal axon development, axon stability, 
degeneration after axotomy, or the ability of WldS to protect severed axons (Fig. 
2-S3). These data argue that additional components of the TER94/VCP complex 
are not involved in Wallerian degeneration or WldS-mediated protection of 
severed axons. 
 
A lack of evidence for a requirement for Sir2 function in WldS-mediated 
axon protection  
Sirt1, a member of the mammalian family of Sir2-like NAD+- binding 
histone deacetylases (the sirtuins), has been implicated in NAD+-mediated axon 
protection through a lentiviral-expressing siRNA study in mammalian tissue 
culture. Specifically, siRNA knockdown of Sirt1, but not the six other mammalian 
sirtuins (Sirt2–7), partially suppressed the ability of NAD+ application to protect 
axons in dorsal root ganglion explant cultures (Araki et al., 2004). Surprisingly, in 
a subsequent study in which a sirt1-null mutation was crossed into the WldS 
background, loss of sirt1 failed to suppress the ability of WldS to protect severed 
axons in vivo (Wang et al., 2005), calling into question the role of Sirt1 in 
executing WldS function. Importantly, it remains an open possibility that the 
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remaining mammalian sirtuins (Sirt2–7) might functionally compensate for Sirt1 in 
this context, and thus, the functional requirements for mammalian sirtuins in WldS 
function remain unclear. 
In Drosophila, there is a single gene that bears strong sequence similarity 
to the mammalian sirtuins, Sir2; Sir2 is 55.9% identical to the Sirt1 at the amino 
acid level. The simplicity of the Drosophila sirtuin family offers the opportunity to 
directly reassess the requirements for sirtuins in WldS function in vivo. We first 
assayed the requirements for Drosophila Sir2 in WldS- mediated protection of 
severed axons using a UAS-regulated RNAi construct targeted to Sir2. We found 
that expression of Sir2RNAi in axons did not induce spontaneous degeneration 
and that ORN axons appeared to develop normally (unpublished data). 
Axotomized Sir2RNAi-expressing axons exhibited normal axon degeneration, 
arguing that Sir2 function is not required for Wallerian degeneration (Fig. 2-6 A). 
Moreover, expression of Sir2RNAi in WldS-expressing axons did not suppress the 
ability of WldS to protect severed axons (Fig. 2-6 A). Next, we confirmed our 
observation with Sir2RNAi genetically by crossing WldS into a Sir2-null mutant 
background. Loss of function alleles of Sir2 are not available; however, removal 
of the Sir2 gene can be accomplished using a heteroallelic combination of the 
two partially overlapping deletions in sir25.2 6 and sir24.5 mutants (Newman et al., 
2002). As with our Sir2RNAi experiments, we found that deletion of the Sir2 gene 
in a WldS background failed to suppress the ability of WldS to protect severed 
axons from degeneration (Fig. 2-6 B). These data argue strongly that WldS does 
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not require the NAD+-binding histone deacetylase Sir2 to protect severed axons 
from autodestruction. 
 
Wallerian degeneration is strongly suppressed by mouse mitochondrial 
Nmnat3, but NAD+ synthase (NADS), membrane-tethered WldS, and 
cytoplasmic Nmnat2 fail to protect severed axons 
Do all NAD+ biosynthetic enzymes protect axons from auto-destruction? 
The Drosophila genome encodes one additional NAD+ biosynthetic enzyme 
called NADS that by primary sequence is not related to Nmnat and in yeast 
localizes throughout the cell (Suda et al., 2003). We generated transgenic flies 
carrying a UAS-NADS construct, drove expression in ORN axons as described in 
the first section of Results, and assayed axon-protective function 5 d after injury 
(Fig. 2-7 A). Surprisingly, NADS provided no protection of axons. To determine 
whether NADS might require VCP/TER94 interactions through N16 for detectable 
axon-protective activity, we also generated flies bearing an N16::NADS fusion 
protein but found that this molecule also completely failed to suppress axon 
autodestruction (Fig. 2-7 A). 
WldS is normally localized in the nucleus, but can WldS protect severed 
axons from degeneration if it is forced to localize elsewhere in the cell? We used 
two approaches to address this question. First, we generated a membrane-
tethered version of WldS. In brief, we fused the extracellular and transmembrane 
domains of the mouse CD8 surface receptor (Lee and Luo, 2001) to the N- 
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terminus of WldS (termed mCD8::WldS) and drove the expression of this 
molecule in 22a+ axons. We found that adult ORNs stably expressed high levels 
of mCD8::WldS in the axonal compartment (Fig. 2-7 B). However, we found that 
mCD8::WldS completely failed to suppress the degeneration of severed axons; 
10 d after axotomy, 100% of mCD8::WldS+ axons degenerated and were cleared 
from the central nervous system (Fig. 2-7 C). Thus, tethering WldS to the cell 
surface in vivo is sufficient to block the ability of WldS to protect severed axons. 
As a second approach, we assayed the protective function of mammalian 
Nmnat molecules that show unique patterns of subcellular localization. In 
mammals, there are three genes encoding Nmnat molecules: Nmnat1, which, as 
described in the first section of Results, localizes to the nucleus; Nmnat2, which 
is cytoplasmic; and Nmnat3, which localizes primarily to mitochondria (Sasaki et 
al., 2006). Nmnat2 localized to the cytoplasm in Drosophila S2 cells (Fig. 2-7 E) 
but completely failed to suppress axon degeneration (Fig. 2-7 D). In striking 
contrast, Nmnat3, which also appeared to localize largely to the cytoplasm in S2 
cells (Fig. 2-7 E), provided levels of axon protection that were indistinguishable 
from those afforded by WldS (Fig. 2-7 D). 
In summary, these data indicate that only a subset of NAD+ biosynthetic 
enzymes can provide significant protection of severed axons, that membrane-
tethered WldS is not sufficient to protect axons, and that Nmnat3, an enzyme that 
localizes primarily to mitochondria in mammalian cells, provides WldS-like levels 
of axon protection. Thus, nuclear localization appears to be nonessential for 
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WldS-like axon protection, and Nmnat3 and WldS appear to have unique activities 
or localizations relative to Nmnat2 and mCD8::WldS that allow for robust axon-
protective function in vivo. 
 
Discussion 
The enzymatic activity of Nmnat1 is a critical feature of WldS  
Whether Nmnat1 and its enzymatic product NAD+ underlie the protective 
activity of WldS has remained a point of great controversy. Two studies found that 
transfection of nmnat1 into dorsal root ganglia neurons or direct application of 
NAD+ or its biosynthetic precursors to dorsal root ganglia cultures was sufficient 
to prolong the survival of severed axons in vitro (Araki et al., 2004; Wang et al., 
2005). In contrast, a subsequent study reported a lack of protection of axons by 
direct expression of Nmnat1 in neurons or application of NAD+ in vitro, and 
transgenic mice expressing Nmnat1 failed to exhibit significant increased axon 
protection in vivo (Conforti et al., 2007). We find that expression of Nmnat1 in 
Drosophila axons provides significant levels of protection for severed axons, with 
the majority of axons surviving for longer than 2 wk. Thus, Nmnat1 is indeed 
strongly neuroprotective on its own, although the levels of protection provided by 
Nmnat1 are significantly reduced compared with WldS. This observation argues 
that Nmnat1 is a critical component of WldS but indicates that the protection 
afforded by WldS and Nmnat1 is not equivalent. As discussed in the following 
section, we propose that the increased efficiency of protection provided by WldS 
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maps to the N16 domain of WldS, which interacts with VCP/TER94. Why doesn’t 
Nmnat1 protect severed axons in transgenic mice? We can think of at least two 
explanations for the difference observed between mice and flies with respect to 
in vivo axon protection by Nmnat1. First, we express Nmnat1 in Drosophila using 
the Gal4/UAS binary expression system, which can drive very high levels of 
expression in ORN neurons. It is possible that we have increased the relative 
amount of Nmnat1 in neurons to a point exceeding that necessary for Nmnat1-
dependent protection of severed axons, whereas expression levels of Nmnat1 in 
mouse sciatic nerve using the β-actin promoter (Conforti et al., 2007) remain 
below this critical threshold. Second, the axons of Drosophila ORNs are much 
shorter than mammalian axons in the sciatic nerve and may thus be more easily 
protected relative to lengthy mammalian axons. 
The protection of severed axons by Nmnat1 critically depends on its 
enzymatic activity. To generate an Nmnat1 molecule that fails to synthesize 
NAD+, we engineered an H24A substitution in Nmnat1. Based on analysis of the 
crystal structure of Methanobacterium thermoautotrophicum NMNAT, the 
corresponding histidine (H19) resides in the binding site for ATP. Mutational 
analysis of the importance of this histidine with an H19A substitution 
demonstrated that mutation of this residue reduced NAD+ biosynthetic activity to 
<1%, did not significantly affect protein folding (determined by solving the crystal 
structure of the H19A mutant version), and led to the copurification of NMNAT 
with its substrate nicotinamide mononucleotide trapped in the active site rather 
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than its product NAD+, which copurifies with wild-type NMNAT (Saridakis et al., 
2001). This suggests a failure of NMNAT to convert nicotinamide mononucleotide 
to NAD+. We find that an H24A substitution in Nmnat1 completely suppresses 
the neuroprotective effects of Nmnat1, with close to 100% of the axons from 
Nmnat1dead-expressing neurons degenerating within 5 d after injury. WldS-dead, 
harboring the same H24A mutation in Nmnat1, also shows dramatically reduced 
efficacy in the protection of severed axons. Together, these data demonstrate a 
requirement for Nmnat1 enzymatic activity in WldS-mediated protection of 
severed axons in vivo. In turn, along with the aforementioned studies, they 
suggest that the effects of Nmnat1 are mediated by its biosynthetic products. 
NAD+ is certainly the best-known product of Nmnat1 enzymatic activity and likely 
plays a key role in axon protection; however, we note that we cannot exclude the 
formal possibility that in the context of axon protection, Nmnat1 may generate 
additional biosynthetic products beyond NAD+ that might be neuroprotective. 
Interestingly, recent work on Drosophila Nmnat (dNmnat) has revealed a 
role for dNmnat1 in the suppression of activity- or spinocerebellar ataxia 1 
(Sca1)–induced degeneration in the visual system (Zhai et al., 2006, 2008). 
Surprisingly, the dNmnat-dependent protection of neurons in the visual system is 
independent of its enzymatic activity, and dNmnat appears capable of acting as a 
chaperone-like molecule in an enzymatic activity–independent manner (Zhai et 
al., 2008). Is this chaperone-like activity contributing to WldS-dependent 
neuroprotection? Although this remains an open possibility, we suspect it is not a 
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major contributing force in the mechanistic action of WldS in severed axons for 
two reasons. First, WldS and Nmnat1 both require their enzymatic activity to 
protect severed axons in vivo, whereas dNmnat can protect against Sca1-
induced neurodegeneration in the absence of enzyme function. Second, dNmnat 
is induced in response to the formation of Sca1 aggregates and localizes to sites 
of protein aggregation, whereas WldS and Nmnat1 show no such localization. A 
more thorough delineation of the mechanistic action of WldS, Nmnat1, and 
dNmnat will be essential to resolve these issues. 
 
N70 contributes to WldS neuroprotective function through interactions with 
VCP/TER94  
How N70 or W18 could contribute to WldS function has remained 
enigmatic. The portion of Ube4b found in WldS, N70, lacks the U box found in 
Ube4b that is essential for E4 ubiquitination activity (Hatakeyama et al., 2001; 
Hatakeyama and Nakayama, 2003) and thus does not have ubiquitin-conjugating 
activity on its own. However, a deletion study of Ube4b has shown that this N-
terminal domain is indeed essential for Ube4b ubiquitination activity (Mahoney et 
al., 2002). Although specific domains necessary for ubiquitination activity of 
mouse Ube4b have not been identified in N70, the first 16 amino acids of N70 
(termed N16) have recently been shown to bind VCP/p97 (Laser et al., 2006). 
Through N16, WldS can redistribute VCP into the nucleus (Dai and Li, 2001). 
VCP, in turn, could result in the association of WldS with a variety of cellular 
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proteins because VCP is capable of binding an array of oligonucleotide- 
ubiquitinated proteins or misfolded proteins and can act to drive their 
polyubiquitination and proteasomal degradation or, alternatively, deubiquitination 
and release of refolded proteins into the cytoplasm (for review see Halawani and 
Latterich, 2006). Consistent with a VCP-dependent recruitment of 
polyubiquitinated proteins to WldS, α-ubiquitin immunoreactivity appears to be 
enriched with WldS in the nucleus in vitro (Laser et al., 2006). 
The aforementioned data provide an exciting link between WldS and 
VCP/polyubiquitin, but a requirement for WldS–VCP interactions or N16 in vivo in 
protecting severed axons has not been demonstrated. In this study, we have 
shown that (a) deletion of the VCP-binding domain N16 from WldS reduces the 
axon-protective ability of WldS to levels indistinguishable from Nmnat1; (b) 
tethering N16 to Nmnat1 is sufficient to provide levels of axon protection 
equivalent to those observed with WldS; (c) WldS associates with Drosophila 
TER94, the fly orthologue of VCP; and (d) knocking down TER94 function in 
WldS-expressing neurons suppresses the axon-protective effects of WldS to 
levels indistinguishable from those observed with Nmnat1. Together, these data 
argue strongly for a role for N16– VCP interactions and VCP function in 
mediating the ability of WldS to protect severed axons. 
How do N16–VCP interactions help WldS protect axons? A simple model 
is that N16–VCP interactions function to redistribute nuclear Nmnat1 activity in 
the cell to a compartment in which its axon-protective effect is maximal. As 
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discussed in the following section, an interesting possibility is that this 
redistribution mimics the localization of Nmnat3 (a mitochondrial Nmnat), which 
appears to protect Drosophila axons in vivo at a level indistinguishable from 
WldS. Alternatively, N16 may bring Nmnat1 together with VCP-associating 
proteins that mediate protective effects. For example, perhaps VCP/TER94 binds 
an unidentified ubiquitinated protein that promotes axon destruction. Because 
WldS redistributes VCP/TER94 to the nucleus, this molecule would in turn be 
titrated out of axons. This effect, combined with the NAD+ biosynthetic capacity 
of Nmnat1, which is partially neuroprotective on its own, could combine for robust 
protection of axons. Alternatively, VCP/TER94 may bring a polyubiquitinated 
NAD+-sensitive molecule into close proximity with Nmnat1, which in turn 
promotes robust axon protection. Identified VCP-binding proteins that mediate 
refolding versus degradative outputs of the VCP complex may not be involved in 
protecting the axons of WldS-expressing neurons. We assayed the ability of 
several VCP-interacting molecules that are essential to promote proteasomal 
degradation of polyubiquitinated proteins (Ufd2 and Npl4/CG4673) or refolding 
and cytoplasmic release of misfolded proteins (Ufd1-like and Plap). Knockdown 
of these molecules in neurons failed to induce widespread spontaneous axon 
degeneration, suppress axon degeneration after axotomy, or reduce the ability of 
WldS to protect severed axons. Although we cannot exclude the possibility that 
RNAi knockdown of these molecules was incomplete, these data begin to argue 
that VCP/TER94 interactions with N16 do not require these molecules for the 
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execution of WldS-mediated axon protection. Further work aimed at defining the 
site of action of WldS and identifying molecules interacting with WldS–
VCP/TER94 complexes in vivo will be essential to clarify these issues. 
Finally, we note that we have defined the minimal domains essential for 
WldS-like levels of neuroprotection as N16::Nmnat1. W18 is not normally a 
domain found in any mouse protein, being generated by the spontaneous fusion 
event in WldS mice, but a role for this domain in axon protection remained an 
open possibility. The deletion of amino acids 17–70 of N70 and W18 in the 
N16::Nmnat1 construct demonstrates that these domains are dispensable for 
WldS-mediated axon protection. 
 
Severed axon autodestruction: the role of nuclear WldS, NAD+, and Nmnat 
activity  
The strong localization of WldS to the nucleus in mice and Drosophila 
provides a compelling argument for a nuclear role for WldS in protecting severed 
axons. Impressively, even expression of high levels of WldS in fly neurons with 
the Gal4/UAS binary system failed to result in detectable axonal localization of 
WldS::Myc in vivo. Despite its clear localization to the nucleus, it has remained 
unclear whether nuclear localization is essential for WldS to protect severed 
axons or whether its presence in the nucleus points to an underlying role in 
modifying gene expression patterns and thereby axon stability. A role for the 
NAD+-binding histone deacetylase Sirt1 in WldS-mediated axon protection seems 
	   58	  
increasingly unlikely; previous work has shown that crossing null alleles of Sirt1 
into the WldS background fails to suppress the ability of WldS to protect axons 
(Wang et al., 2005), and we show that loss of the Drosophila orthologue of Sirt1, 
Sir2, does not affect the ability of WldS to protect severed axons in vivo. 
Interestingly, we found that tethering WldS to the membrane by fusing it with 
mCD8 completely suppressed the ability of WldS to protect severed axons; 
therefore, the presence of membrane-tethered (likely) monomers of WldS is 
insufficient for any level of axon protection, suggesting that localization or free 
solubility of WldS is important to its function. 
Are changes in NAD+ production responsible for the axon-protective 
effects of WldS? To further explore the role of NAD+ biosynthesis in suppressing 
axon autodestruction, we assayed the ability of various Drosophila and 
mammalian NAD+ biosynthetic enzymes to block Wallerian degeneration. 
Surprisingly, of the four NAD+ biosynthetic molecules we tested, only two, 
Nmnat1 and Nmnat3, protected severed axons from autodestruction. Nmnat2, 
which localizes to the cytoplasm in mammalian and Drosophila cells, exhibited no 
protective effect. Likewise, NADS, an NAD+ biosynthetic molecule that generates 
NAD+ from a different pool of precursors than Nmnat (Rongvaux et al., 2003), 
failed to protect severed axons from degeneration. In striking contrast, Nmnat3, 
which localizes to mitochondria in mammals and throughout the cytoplasm in 
Drosophila cells, provided robust protection of axons at levels indistinguishable 
from those afforded by WldS 5 d after injury. These observations raise several 
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important points: (a) not all NAD+ biosynthetic enzymes are capable of 
suppressing Wallerian degeneration, which argues that Nmnat1 and Nmnat3 are 
somehow unique in localization, protein–protein interactions, or enzymatic 
activity, which results in axon-protective activity; (b) the fact that multiple NAD+ 
biosynthetic enzymes protect severed axons may indicate that changes in NAD+ 
are a key factor in suppression of Wallerian degeneration; (c) Nmnat3 is not 
expected to bind VCP/TER94 but can protect axons at levels equivalent to WldS; 
thus, N16–VCP interactions do not appear to be essential for WldS-like 
neuroprotection by Nmnat molecules; and (d) Nmnat3 localizes outside the 
nucleus in Drosophila and mammals, arguing that nuclear localization of Nmnat 
activity is not essential for robust axon protection. Interestingly, it was recently 
found that Nmnat1 and Nmnat3 can also suppress degeneration induced by 
rotenone, an activator of mitochondrial oxidative stress (Press and Milbrandt, 
2008). This observation, coupled with the robust protection of axons we observe 
with Nmnat3, may point to a role for WldS/Nmnat activity in mitochondria for axon 
protection. In the future, it will be critical to define the site of action of WldS and 
Nmnat3 and determine whether they are protecting axons by similar 
mechanisms. 
The WldS mutation protects axons through gain of function mechanisms. 
Is WldS telling us that axons initiate an active axon autodestruction pathway akin 
to cell death, as has been previously speculated (Coleman and Perry, 2002; Raff 
et al., 2002), or is WldS an aberration that fortuitously blocks Wallerian 
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degeneration? Based on work in other invertebrates, we favor the notion that 
axons in mice, Drosophila, and many other species indeed initiate an active 
process of autodestruction after axotomy. A considerable literature exists 
supporting the ability of severed axons in both vertebrates and invertebrates to 
exhibit long-term survival (Bittner, 1991). A striking example comes from two 
species of crickets, Teleogryllus commodus and Gryllus bimaculatus. In these 
animals, behavioral rhythmicity is governed by a small number of pigment-
dispersing factor–positive neurons whose cell bodies reside in the optic lobes. 
The removal of cell bodies fails to induce degeneration of severed pigment- 
dispersing factor–positive axons, which can survive for up to 90 d after axotomy, 
and, impressively, behaviors subject to circadian control remain robust, indicating 
that severed surviving axonal stumps remain functionally intact for many weeks 
after axotomy (Stengl, 1995). Why some axons spontaneously degenerate after 
injury whereas others do not is unknown, but defining the molecular pathways 
that account for these striking differences in the axonal survival and precisely 
how WldS impinges upon these pathways will be an extremely important future 
goal to further our understanding of the basic cellular mechanisms by which 
neurons maintain the functional integrity of axons. Our findings point to the 
importance of defining molecules downstream of WldS, perhaps outside the 
nucleus, that interact with VCP or NAD+, and we suggest that these will be key 
modulators of Wallerian degeneration. 
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Materials and Methods 
Drosophila stocks and transgenics  
The following stocks were used: OR22a-Gal4 (a gift from J. Carlson, Yale 
University, New Haven, CT); pUAST-mCD8–GFP, GH146-Gal4, and elav- Gal4 
(a gift from T. Lee, University of Massachusetts Medical School, Worcester, MA); 
Sir24.5 and Sir25.26 (a gift from S. Smolik, Oregon Health and Science 
University, Portland, Oregon); UAS-Ter94RNAi, UAS-CG4673RNAi, UAS-
CG9934RNAi, UAS-PlapRNAi, and UAS-Ufd1–likeRNAi (Vienna Drosophila 
RNAi Center); and UAS-Sir2-RNAi (National Institute of Genetics Stock Center). 
pUAST-WldS::myc was created by PCR amplifying a 1.1-kb fragment from 
pUAST-WldS and fusing six tandem Myc tags onto the C terminus of WldS using 
the primers 5!-GATCAGATCTCAAAACATGGAGGAGCT- GAGCGCTGAC-3! 
and 5!-ATAATCCGCGGCAGAGTGGAATGGTTGT- GCTTG-3! and 
subsequently subcloning this fragment into pUAST with BglII and SacII.  
pUAST-Nmnat1 was created by subcloning mouse nmnat1 (858 bp from 
Mus musculus) from pHSVPrPUC (a gift from Z. He, Harvard University, 
Cambridge, MA) into pBluescript-KS with BamHI and EcoRI. It was then 
subcloned from pBluescript-KS into pUAST with BamHI and XhoI cut sites and 
was subsequently subcloned into pUAST using BglII and XhoI cut sites. 
Nmnat1dead was subcloned in the same manner but carries the H24A mutation 
(a gift from Z. He). 
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pUAST-WldS-dead was created by subcloning WldS from pUAST (a gift from L. 
Luo, Stanford University, Stanford, CA) to pBluescript-KS using EcoRI and XbaI, 
and then a 245-bp C-terminal fragment including the H24A mutation was used to 
replace the corresponding region of nmnat1. The resulting 1.1-kb fragment (WldS-
dead) was then subcloned from pBluescript-KS into pUAST.  
pUAST-WldS-ΔN16 was created by cloning amino acids 17–373 of WldS into 
pUAST with BglII and XhoI and adding a 5! Met-encoding codon using the 
primers 5!-GATCAGATCTCAAAACAT- GCTTGCTGGTGGACAGACCTCCC-3! 
and 5!-TATACTCGAGTCACAGA- GTGGAATGGTTGTGCTTGGCC-3!. 
pUAST-N16::nmnat1 was created by subcloning N16 into pUAST and 
subsequently amplifying an 850-bp fragment of M. musculus nmnat1 using the 
primers 5!-GAATGCTAGCATGGACTCATCCAAGAAGACAGA- GGTGG-3! and 
5!-TATACTCGAGTCACAGAGTGGAATGGTTGTGCTTG- GCC-3! and then 
subcloning this fragment into pUAST-N16 with NheI and XhoI.  
pUAST-mCD8::WldS was created by amplifying a 672-bp fragment 
encoding the extracellular and transmembrane domains of mCD8 from pUAST-
mCD8::GFP (Lee and Luo, 2001) and subcloning it into pBluescript-KS using 
BglII and XbaI. The WldS open reading frame was then subcloned into this 
plasmid using engineered BglII and XbaI sites to generate pBluescript-KS–
mCD8::WldS. mCD8::WldS was then subcloned into pUAST using BglII and XbaI 
to generate pUAST-mCD8::WldS. 
pUAST-Nmnat1::myc was created by amplifying Nmnat1 from the pUAST vector  
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(as described for pUAST-Nmnat1) with the primers 5!-GGC- 
GAGATCTCAAAACATGGACTCATCCAAGAAGACAGAGGTGG-3! and 5!-
TATTAATCCGCGGCAGAGTGGAATGGTTGTGCTTGG-3! and was 
subsequently cloned into the C-terminal myc pUAST vector with BglII and SacII.  
pUAST-Nmnat2 was amplified from mouse cDNA clone BC098007 (Open 
Biosystems) using the primers 5!-AATTGATTGCGGCCGCAAAA- 
CATGACCGAGACCACAAAGACC-3! and 5!-AATTGTCTAGACTAGCCC- 
GAGGCGTTGATGTACAGC-3! and subsequently cloned into pUAST with NotI 
and XbaI.  
pUAST-Nmnat2::myc was amplified from the same clone as Nmnat2 with 
the primers 5!-AATTGATTGCGGCCGCAAAACATGACC- 
GAGACCACAAAGACC-3! and 5!-ATTAATATTAGCGGCCGCGTGCCC- 
GAGGCGTTGATGTACAGCTGACTCTTGAG-3! and subsequently cloned into 
C-terminal myc pUAST vector with NotI. 
pUAST-Nmnat3 was amplified from mouse cDNA clone BC092086 (Open 
Biosystems) using the primers 5!-ACTTATATGCGGCCGCAAAA- 
CATGAAGAACCGAATTCCCTGTGGTGC-3! and 5!-AGCAGTCTAGAC- 
TAGCCAGTCTTTCCTTTCCC-3! and was subsequently cloned into pUAST with 
NotI and XbaI.  
pUAST-Nmnat3::myc was amplified from the same clone as Nmnat3 using 
the primers 5!-ACTTATATGCGGCCGCAAAACAT- 
GAAGAACCGAATTCCCTGTGGTGC-3! and 5!-TATAATTAGCGGCCGC- 
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GTGCCAGTCTTTCCTTTCCCTTTCCAGGAACCGTCATTGATG-3! and was 
subsequently cloned into C-terminal myc pUAST vector with NotI. 
pUAST-NADS was amplified from cDNA clone LD11409 (Berkeley 
Drosophila Genome Project) using the primers 5!-GATCGAATTCCAAAA- 
CATGGGACGCAAGGTGACCGTAGCGG-3! and 5!-GATCCTCGAGC- 
TAGACGGGAATACCGGTGCGA-3! and was subsequently cloned into pUAST 
with EcoRI and XhoI. 
 pUAST-N16::NADS was amplified from the same clone as NADS with the 
primers 5!-GATCGAATTCCAAAACATG- 
GAAGAACTGAGCGCGGATGAAATTCGCCGCCGCCGCCTGGCGCG- 
CATGGGACGCAAGGTGACCGTAGCGG-3! and 5!-GATCCTCGAGC- 
TAGACGGGAATACCGGTGCGA-3! and subsequently cloned into pUAST with 
EcoRI and XhoI. 
 
Axon injury protocol 
Antennal ablations were performed on animals carrying OR22a-Gal4, UAS-
mCD8::GFP, and the indicated constructs. 1 wk after eclosion, both third 
antennal segments were surgically ablated with tweezers, and the flies were kept 
at 25°C until dissection (5, 10, 15, 20, or 30 d), as indicated in Figs. 3–7 and 
Figs. S2 and S3. Uninjured flies were dissected 1 wk after eclosion unless 
denoted in legends as age matched. Adult heads were fixed with 4% 
formaldehyde (Sigma-Aldrich) in 1× PBS and 0.1% Triton X-100 (PTx; Sigma-
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Aldrich) for 20 min before dissection and washed five times with PTx. Dissected 
brains were subsequently fixed in 4% formaldehyde in PTx for 10 min and 
washed five times with PTx and three times with 1× PBS/0.1% Triton X-100/1% 
BSA (PBT; Thermo Fisher Scientific). Brains were rocked for 30 min in PBT at 
room temperature, and primary antibodies were added in PBT and rocked 
overnight at 4°C. Brains were washed 10 times over 1.5 h with PBT, and 
secondary antibodies were added in PBT. Brains were rocked for 3 h in 
secondary antibody at room temperature and subsequently washed 10 times 
over 1.5 h with PBT. Brains were stored at 4°C in antifade reagent (Bio-Rad 
Laboratories). In the case of animals expressing GFP, no antibodies were used 
to enhance the GFP signal. 
 
Immunolabeling, confocal microscopy, and quantification of axon 
protection  
Standard methods were used for dissection, fixation, and antibody labeling of the 
Drosophila adult brain (MacDonald et al., 2006). Primary antibodies were used at 
the following dilutions: 1:1,000 for immunolabeling of mouse tissue with α-Myc 
(9E10; Covance), 1:500 for Western blot analysis of α-VCP (BD), and 1:250 for 
rabbit α-Nmnat1 (a gift from M. Cole- man, Babraham Institute, Cambridge, 
England, UK). Secondary antibodies (Cy3; Jackson ImmunoResearch 
Laboratories) for immunolabeling of tissues were used at 1:200. Specimens were 
mounted in a 1:1 mixture of antifade reagent and 75% glycerol. Confocal z stacks 
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of antennal lobes and S2 cells were collected on a confocal microscope 
(Axioskop2 LSM 5 Pascal; Carl Zeiss, Inc.) with a Plan Apochromat 63× NA 1.4 
objective lens (Carl Zeiss, Inc.), which was also equipped with a transmitted light 
detector used for acquisition of differential interference contrast images of S2 
cells. All confocal microscopy was performed at room temperature (21°C) using 
acquisition software (LSM 5 Pascal; Carl Zeiss, Inc.). Confocal images were 
compressed with ImageJ software (National Institutes of Health), and intact 
GFP+ axons were counted individually at the indicated time points. At least two 
lines (in most cases three to four) were assayed for each construct, results 
among lines carrying the same construct were indistinguishable from one 
another, and data were subsequently pooled. 
 
Immunoprecipitations from S2 cell extracts 
Drosophila S2 cells were counted and plated at 1 × 106 cells/ml, incubated 
overnight at 30°C, transfected with pUAST-WldS::myc and pAC- Gal4 according 
to the instructions in the Transfectene kit (QIAGEN), and incubated for 48 h. 
Protein G–Sepharose fast-flow beads (GE Healthcare) were washed in extraction 
buffer (150 mM NaCl, 1% Igepal CA630, 50 mM Tris, pH 7.5, and 1× EDTA-free 
complete protease inhibitor) and bound with α-Myc antibody for 3 h at 4°C. 
Transfected and untransfected cells were isolated and centrifuged at 3,000 rpm 
for 5 min at 4°C. Cells were resuspended in extraction buffer and placed in 
ethanol/dry ice bath for 5 min, thawed in a cold ice bath, homogenized, and 
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centrifuged at 11,000 rpm for 10 min at 4°C. A fraction of the supernatant was 
reserved as input, and remaining samples were precleared with equilibrated 
protein G– Sepharose beads for 2 h at 4°C, added to α-myc–conjugated protein 
G– Sepharose beads, and incubated at 4°C overnight. The samples were then 
centrifuged at 2,000 rpm for 1 min. A portion of the supernatant was reserved as 
the flow-through sample, and the remaining supernatant was discarded; beads 
were washed five times with extraction buffer, and bound protein was eluted from 
beads with SDS-PAGE loading buffer. 
 
S2 cell transfection and immunolabeling 
Drosophila S2 cells were counted and plated at 1 × 106 cells/ml, incubated 
overnight at 30°C, and transfected with pUAST-WldS::myc and pAC-Gal4 
according to the instructions in the Transfectene kit. Cells were then fixed in PEM 
(Pipes, EGTA, and MgCl2 buffer)/4% formaldehyde and washed with PBT. 
Primary antibody (α-myc) was added to the cells at 1:1,000, cells were washed, 
and secondary α-mouse anti- bodies were added at 1:200. Immunolabeling was 
then viewed with confocal microscopy. 
 
Online supplemental material 
Fig. S1 shows how the quantification of intact axons was counted. Fig. S2 
compares the various transgenes of each construct to show that expression level 
variations did not affect the protection level. Fig. S3 shows RNAi experiments of 
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proteins thought to complex with VCP/Ter94, none of which appear to have a 
role in WldS-mediated protection. Online supplemental material is available at 
http://www.jcb.org/cgi/content/full/ jcb.200808042/DC1. 
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Figure 2-1 
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Figure 2-1. Constructs used to dissect WldS functional domains and 
localization in Drosophila neurons. (A) All constructs were generated from 
mouse WldS, which contains N70, the first 16 amino acids (N16) that encode the 
VCP-binding site, W18, an 18–amino acid linker, and full-length Nmnat1. 
Nmnat1dead harbors an H24A mutation; WldS-ΔN16 lacks the N16 domain; 
N16::Nmnat1 is N16 tethered to the N terminus of Nmnat1; WldS-dead is full-length 
WldS with an H24A mutation in Nmnat1. See Materials and methods for details. 
(B–G) UAS-WldS::Myc (B and C), UAS-WldS-dead::Myc (D and E), and UAS-
Nmnat1::myc (F and G) were expressed with UAS-mCD8::GFP in projection 
neurons using GH146-Gal4. The arrows point to nuclei, and the arrowheads 
point to axons. Bar, 12.14 µm. 
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Figure 2-2
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Figure 2-2. WldS variant proteins are stably expressed in Drosophila 
neurons. Three independent UAS-driven transgene insertion lines for each WldS 
variant molecule were crossed to elav-Gal4, and protein extracts from heads 
were assayed for expression using α-Nmnat1 antibodies. Multiple lines for each 
construct were found to express detectable levels of protein. The expression of 
each of these molecules in ORNs with OR22a-Gal4 did not lead to expression of 
proteins at levels detectable by Western blot analysis (not depicted). Molecular 
masses are shown in kilodaltons. MW, molecular weight. 
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of severed axons in animals expressing Wld S remained intact 
even 30 d after injury (77%), whereas a minority of axons ex-
pressing Nmnat1 (32%) remained intact at this time point. 
Thus, Nmnat1 is indeed a neuroprotective molecule in vivo 
and likely represents an important component of the severed 
axon-protecting activity of Wld S . However, the fact that Nmnat1 
provided signi! cantly reduced protection of severed axons 
compared with Wld S argues that N70 and/or W18 enhances 
the neuroprotective nature of Nmnat1 in important ways to pro-
vide Wld S -like levels of axon protection. 
enzymatic activity was essential for axonal protection. Previ-
ously, we reported that mouse Wld S could robustly suppress 
Wallerian degeneration in  Drosophila for at least 20 d after in-
jury ( MacDonald et al., 2006 ). We have now con! rmed and 
extended this ! nding to 30 d after injury, with the majority 
(77%) of Wld S -expressing axons remaining intact for this pe-
riod ( Fig. 3 ). Interestingly, we found that expression of mouse 
Nmnat1 in ORNs also partially suppressed Wallerian degener-
ation; however, Nmnat1 was signi! cantly less effective than 
Wld S at protecting severed axons. For example, the majority 
 Figure 2.  Wld S variant proteins are stably expressed in 
 Drosophila neurons. Three independent UAS-driven trans-
gene insertion lines for each Wld S variant molecule were 
crossed to  elav-Gal4 , and protein extracts from heads were 
assayed for expression using  ! -Nmnat1 antibodies. Multiple 
lines for each construct were found to express detectable 
levels of protein. The expression of each of these molecules 
in ORNs with  OR22a-Gal4 did not lead to expression of 
proteins at levels detectable by Western blot analysis (not 
depicted). Molecular masses are shown in kilodaltons. MW, 
molecular weight. 
 Figure 3.  Wld S requires N70 and Nmnat1 
biosynthetic activity for maximal protection of 
severed axons in vivo. UAS-regulated versions 
of Wld S variants were expressed in OR22a + 
ORNs with  OR22a-Gal4 , axons were severed, 
and the number of remaining intact GFP + axons 
was scored at the time points indicated. Two 
to four independent insertion lines were tested 
for each UAS-regulated Wld S variant molecule 
(Fig. S1, available at http://www.jcb.org/
cgi/content/full/jcb.200808042/DC1);  n  ≥ 
10 for individual lines; data were subsequently 
pooled and are presented here. For Nmnat1, 
**, P  < 0.01 and ***, P  < 0.001 (Nmnat1 vs. 
Wld S at corresponding time points). For Wld S , 
**, P  < 0.01 (day 0 vs. day 30). Error bars 
represent SEM. 
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Figure 2-3. WldS requires N70 and Nmnat1 biosynthetic activity for maximal 
protection of severed axons in vivo. UAS-regulated versions of WldS variants 
were expressed in OR22a+ ORNs with OR22a-Gal4, axons were severed, and 
the number of remaining intact GFP+ axons was scored at the time points 
indicated. Two to four independent insertion lines were tested for each UAS-
regulated WldS variant molecule (Fig. S1, available at http://www.jcb.org/ 
cgi/content/full/jcb.200808042/DC1); n ≥ 10 for individual lines; data were 
subsequently pooled and are presented here. For Nmnat1, **, P < 0.01 and ***, P 
< 0.001 (Nmnat1 vs. WldS at corresponding time points). For WldS, **, P < 0.01 
(day 0 vs. day 30). Error bars represent SEM. 
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Figure 2-4 
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Figure 2-4. N16 is the key domain in the N terminus of WldS that is 
essential for WldS-like axon protection. WldS, Nmnat1, ΔN16-WldS, and 
N16::Nmnat1 were expressed in ORNs using OR22a-Gal4, axons were severed, 
and the number of remaining intact GFP+ severed axons were scored at the time 
points indicated. n ≥ 10 for all genotypes; **, P < 0.01. Error bars represent SEM. 
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Figure 2-5 
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Figure 2-5. WldS localizes to the nucleus in Drosophila S2 cells and 
associates with TER94, and TER94 is essential for WldS-like levels of axon 
protection. (A and B) S2 cells were transfected with WldS::myc and stained with 
α-Myc antibodies, and α-Myc immunoreactivity localized to the nucleus. (C) 
Immunoprecipitation (IP) from WldS::Myc–transfected cell lysates with α-Myc 
antibodies led to the purification of a 97-kD isoform of Ter94. HC, heavy chain 
from α-Myc IgG; WB, Western blot. (D) UAS-Ter94RNAi was driven in OR22a+ 
ORNs in the presence or absence of WldS. n ≥ 10 for all genotypes; *, P < 0.05; 
**, P < 0.01; ***, P < 0.001. Error bars represent SEM. Bar, 13.56 µm. 
	   79	  
 
Figure 2-6 
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Figure 2-6.  Sir2 is not required for WldS-mediated protection of severed 
axons. (A) UAS-Sir2RNAi was driven in OR22a+ ORNs with OR22a-Gal4 in the 
presence or absence of WldS, and axons were assayed 15 d after injury. (B) The 
requirements for Sir2 in WldS-mediated axon protection were assayed 15 d after 
injury in WldS-expressing axons and WldS axons that lacked sir2 (sir24.5/sir25.26). 
WldS, n = 10; Sir2 -/-" + WldS, n = 6. Error bars represent SEM. 
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Figure 2-7 
Figure 2-7. Axon-protective function of NAD+- producing enzymes is 
specific to Nmnat1 and -3, and Nmnat3 protects as well as WldS. (A) NADS 
and N16::NADS were expressed in ORNs using OR22a-Gal4, and axons were 
severed and analyzed for protection 5 d after axotomy. (B) Localization of 
mCD8::WldS was assayed using α-CD8 antibodies, and expression of 
mCD8::WldS was driven in ORNs using the OR22a-Gal4 driver. Axons are 
indicated projecting to glomeruli (arrowhead) and across the midline (arrow), and 
OR22a+ ORN- innervated glomeruli are shown with dashed lines. (C) 
Membrane-tethered WldS (mCD8::WldS) was assayed for axon-protective 
function 10 d after axotomy. n ≥ 10 for all genotypes. (D) Nmnat2 and -3 were 
driven by OR22a-Gal4 in ORNs to assay for protective function 5 d after 
axotomy. n ≥ 10 for all genotypes; **, P < 0.01; ***, P < 0.001. (E) S2 cells were 
transfected with Nmnat2::myc and Nmnat3::myc and stained with α-myc. In both 
cases, α-myc immunoreactivity was localized to the cytoplasm but not the 
nucleus. DIC, differential interference contrast. Error bars represent SEM. Bars: 
(B) 27.47 µm; (E) 14.71 µm. 
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Figure 2-S1 
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Supplementary Figure 2. Representative images of UAS-22a-Gal4, mcd8::GFP
axons and glomeruli expressing either UAS-Wlds, UAS-Nmnat1, or neither. The
uninjured lobe has 13 intact axons. By day 5 all control axons are degenerated
(arrows). UAS-Wlds-expressing lobe shows 11 intact axons 20 days after injury. In
contrast, the UAS-Nmnat1-expressing lobe only shows 4 intact axons at this
timepoint (arrow points to a fragmented axon).
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Figure 2-S1. Representative images of UAS-22a-Gal4, mcd8::GFP axons 
and glomeruli expressing either UAS-WldS, UAS-Nmnat1, or neither. The 
uninjured lobe has 13 intact axons. By day 5 all control axons are degenerated 
(arrows). UAS-WldS-expressing lobe shows 11 intact axons 20 days after injury. 
In contrast, the UAS-Nmnat1-expressing lobe only shows 4 intact axons at this 
timepoint (arrow points to a fragmented axon). 
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Figure 2-S2 
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Supplementary Figure 1.  
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Figure 2-S2.  Axonal protection afforded by WldS variant transgenes. (A–F) 
UAS-regulated transgenes were driven in ORNs with OR22a-Gal4, axons were 
severed by antennal ablation, and the number of intact GFP+ axons was scored 
at the time points indicated. Transgene insertion line identifiers are indicated, and 
two to four insertion lines were assayed for each transgene. Note that not all x 
axes are the same among different lines (days after injury) because constructs 
that lost efficacy were not assayed at later time points. UAS-WldS (A), UAS-WldS-
dead (B), UAS-Nmnat1 (C), UAS-Nmnat1dead (D), UAS- N16::Nmnat1 (E), and 
UAS-WldSΔN16 (F) are shown. n > 10 for all genotypes for all time points. Error 
bars represent SEM. 
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Figure 2-S3 
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Figure 2-S3.  RNAi knockdown of VCP/TER94 interacting molecules does 
not suppress axon degeneration or the ability of WldS to protect severed 
axons. The ability of Npl4, Ufd2, Ufd1-like, and Plap to modulate severed axon 
autodestruction or the neuroprotective effects of WldS were assayed by 
expressing UAS-regulated RNAi transgenes targeting each with OR22a-Gal4, 
severing axons, and assaying protection 15 d after transection. RNAi knockdown 
of these genes had no effect on Wallerian degeneration, and the ability of WldS to 
suppress axon autodestruction was not suppressed. n>10 for all genotypes; *, P 
< 0.05. Error bars represent SEM. 
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Chapter III: 
Wlds requires increased mitochondrial motility 
and Ca2+-buffering efficiency for severed axon 
protection 
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Introduction 
Neurodegenerative diseases have many different causes, however, the 
death of neurons is a common result.  Recently, it has been found that many 
neurodegenerative diseases share mitochondria dysfunction as either a common 
byproduct or possibly even cause of disease (Celsi et al., 2009; Chen and Chan, 
2009).  It is of particular interest that Wlds, a highly neuroprotective molecule, has 
been found to be localized to mitochondria (Yahata et al., 2009). When 
expressed in neurons, Wlds can cell-autonomously protect axons from physical 
injury, neurotoxicity, and some neurodegenerative diseases (Coleman, 2005).  
Wlds is a novel fusion protein consisting of: (1) the first 70 amino acids of Ube4b, 
an E4 ubiquitin ligase, (2) an 18 amino acid linker sequence and  (3) full-length 
Nmnat1, a key enzyme in NAD+ synthesis (Mack et al., 2001). Only the first 16 
amino acids of Ube4b and full-length Nmnat1 are required for Wlds-like protection 
(Avery et al., 2009).  Although we know that N16 is required for Wlds-like 
protection, its function is axon protection is unknown.  It is possible that N16 
serves to relocalize Nmnat1 to the mitochondria as Nmnat3, a mitochondrial 
protein, can protect as well as Wlds in both mammals and Drosophila.  Other 
studies that have mislocalized Nmnat1 outside of the nucleus find its 
neuroprotective ability increases greatly (Avery et al., 2009; Yahata et al., 2009; 
Sasaki et al., 2009; Beirowski et al., 2009; Babetto et al., 2010). 
 Studying the mitochondria of Wlds-expressing animals is of utmost 
importance to see if there are detectable biological changes which could account 
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for the differences seen in Wallerian degeneration between a wild-type and Wlds 
animal.  In this study, we examine mitochondria as the potential site of Wlds 
action.  We extend our finding that Nmnat3 can protect axons after axotomy as 
well as Wlds to 50 days after injury.  We also report the first biological changes 
seen in neurons expressing Wlds, and find key changes in mitochondrial biology: 
Wlds causes the number of stationary mitochondria to decrease; and the Wlds 
decreases the amount of Ca2+ in the cell after axotomy.  We find that 
suppressing the increase in mitochondrial movement can suppress Wlds 
protection of axons after injury.  Finally, we propose that Wlds, functioning 
through the mitochondria to increase Ca2+ buffering, suppresses a degeneration 
signal after axotomy.   
Results 
We have previously shown that expression of mouse Nmnat3, a reported 
mitochondrial protein, in Drosophila olfactory receptor neurons (ORNs) was able 
to protect severed axon from degeneration as well as Wlds 5 days after injury 
(Avery et al., 2009).  It was also recently found that Wlds localizes to 
mitochondria, and that expression of Nmnat3 can protect severed axons in the 
mouse as well (Yahata et al., 2009 and T. Gillingwater, personal communication).  
This led us to further investigate the protective ability of Nmnat3.   
First we wanted to confirm the localization of mouse Nmnat3 to 
mitochondria in Drosophila.  UAS-Nmnat3::myc was  driven by the olfactory 
receptor neuron (ORN) driver, 22aGal4, along with UAS-mito-GFP to label the 
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mitochondria.  Nmnat3::myc was found to colocalized with mito-GFP in 
Drosophila ORNs (Fig 3-1A).  Next, we wanted to extend the timepoints of our 
Wallerian degeneration assay to compare the protective ability Wlds and Nmnat3.  
To do so, UAS-Nmnat3 was driven by ORN-22aGal4.  We found that Nmnat3 
protective ability is similar to Wlds at 10, 20, and 50 days after ablation, with a 
strong protection at days 10 and 20 and a significant decrease in protection at 
day 50 (Fig 3-1B).  It should be noted that two other Nmnat molecules, Nmnat1, 
which localizes to the nucleus of Drosophila neurons, and Nmnat2, which 
localizes to the cytoplasm of ORNs, is unable to protect severed axons from 
degeneration (Fig 3-S1 and Avery et al., 2009).  Thus, mitochondrial localization 
of Nmnat activity is critical for full axon protection from severed axon auto 
destruction.   
 Recent reports have stated that expression of Nmnat2 can protect axons 
in vitro from axotomy-induced degeneration (Yan et al., 2009 and Gilley and 
Coleman, 2010).  However, this protection is much weaker than that of Wlds, and 
is thought to be due to the short half-life of Nmnat2.  To test the possibility that 
Nmnat2 is degraded at 5 post-axotomy and thereby accounting for the lack of 
protection seen in Drosophila ORNs, we drove UAS-Nmnat2::myc along with 
UAS-Wlds so that the axon would still be intact 5 days after axotomy.  In all 
cases, Nmnat2::myc was present in the axon 5 days after axotomy (data not 
shown).  Therefore, a shortened half-life cannot account for the lack of 
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protection, but instead, we postulate Nmnat2 is not in the right location for 
protection, the mitochondria.    
 The mitochondrial localization of both Nmnat3 and Wlds along with their 
impressive protection against Wallerian degeneration, led us to look at the 
mitochondria themselves for changes in size, number, and movement.  For this, 
we turned to 3rd instar larval fillet preparations for live imaging.  We created 5 
minute movies using UAS-CD2::RFP or UAS-mCherry driven by Tdc2Gal4 to 
visualize the axons, and UAS-mito-GFP to label the mitochondria (Fig 3-2A).  
We then quantified the number, size, speed, direction, and movement of 
mitochondria (Fig 3-2B, 3-S2, and data not shown).  Surprisingly, the only 
change observed in the mitochondria expressing Wlds was that the number of 
stationary mitochondria decreased greatly (Fig 3-2C).  Figure 3-2B shows 
representative kymographs of control and Wlds; the vertical lines represent 
stationary mitochondria, whereas diagonal lines are moving mitochondria.  We 
also quantified the mitochondria movement when driving other molecules found 
to be neuroprotective in axon degeneration in our previous work (Avery et al., 
2009).  Strikingly, the number of stationary mitochondria correlated indirectly with 
the degree of protection against axon degeneration at 5 days after injury (Fig 3-
2B); weakly protective molecules slightly decrease the number of stationary 
mitochondria, whereas highly protective molecules greatly decrease the number 
of stationary mitochondria.  Thus, more mitochondria are moving in the presence 
of Nmnat-containing neuroprotective molecules.  This observation is the first 
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biological change that has been seen in vivo in a Wlds-expressing neuron prior to 
injury, and may be indicative of Wlds function. 
 To test if the increase in motile mitochondria is necessary for axon 
protection of Wlds, we assayed mutants that would inhibit mitochondrial 
movement.  Miro, an atypical Rho GTPase, is responsible for both antero- and 
retro- grade movement of mitochondria (Russo et al., 2009).  It localizes to the 
outer membrane of mitochondria and either binds to the kinesin via an adaptor 
protein, Milton, or binds the kinesin heavy chain itself (Guo et al., 2005; Glater et 
al, 2006, MacAskill et al., 2009).  While mutations in Miro render the axon almost 
completely devoid of mitochondria, heterozygous alleles as well as 
overexpression of Miro in Drosophila neurons causes a reduction in the number 
of moving mitochondria (Guo et al., 2005; Russo et al., 2009).  Allelic loss of Miro 
does not affect the number of mitochondria in an axon, and the overexpression of 
Miro reduces the number of mitochondria present in axons; however this 
reduction of mitochondria does not have an effect on ORN viability (Russo et al., 
2009; Fig 3-S3).  To test whether Miro alleles and overexpression are able to 
suppress the decrease in stationary mitochondria seen in Wlds-expressing flies, 
we again looked at open filet preparations of 3rd instar wandering larvae.  Five 
minute movies were made of Tdc2Gal4 driving UAS-CD2-RFP or mCherry to 
mark the axons, UAS-mito-GFP to label the mitochondria, UAS-Wlds, and one of 
the following: MiroSD32/+, MiroSD26/+, or UAS-myc::Miro/+.  We also looked at the 
alleles and overexpression line without Wlds.  As previously reported, the 
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heterozygous alleles and overexpression line were able to increase the amount 
of stationary mitochondria (Fig 3-S4, Russo et al., 2009).   Surprisingly, Miro 
alleles and overexpression line suppressed the decrease in stationary 
mitochondria seen in Wlds-expressing (Fig 3-3A).  Moreover, the number of 
stationary mitochondria in Wlds-expressing flies with either Miro allele actually 
increased compared to wild-type (Fig 3-3A). 
 To test if suppressing the movement of mitochondria had an effect on 
axon protection, we again used our model of Wallerian degeneration in the adult 
ORNs.  We drove UAS-mCD8::GFP with OR-22a-Gal4, along with Wlds and 
either of the Miro alleles or UAS-myc::Miro.  Allelic loss of Miro and UAS-myc-
Miro on their own do not affect uninjured axon integrity or degeneration after 
injury (Fig. 3-S4).  MiroSD32/+, MiroSD26/+, and UAS-myc::Miro/+ also do not have 
an effect on uninjured axons expressing Wlds (Fig 3-3B).  However, Miro 
heterozygous alleles and overexpression have a striking dominant suppression 
of Wlds protection at 5, 15, and 30 days after ablation (Fig 3-3B).  It is also 
important to note that the axons surviving at those times points appear to have 
morphological defects, such as the presence of blebs, which are not seen in Wlds 
alone expressing flies after injury (Fig 3-3C).  Therefore, an increase in 
mitochondrial movement is necessary for Wlds to protect severed axons after 
axotomy. 
 What does the increase in moving mitochondria mean?  Mitochondria are 
known to be major Ca2+ sinks in the cell.  In order to buffer the Ca2+, they need to 
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be able to sense changes in cytoplasmic Ca2+.  Miro has 2 EF hand domains that 
are known to be able to bind Ca2+ (MacAskill et al., 2009).  When Miro binds to 
Ca2+, the mitochondria either dissociate from the kinesin or bind the motor 
domain of the kinesin directly, making it detach from microtubules (MacAskill et 
al., 2009; Wang and Schwarz, 2009).  The effect in either case is the freezing of 
mitochondria at local pools of high Ca2+.  Such a high Ca2+ sensitivity enables 
mitochondria to get to and remain in areas where an increase in energy 
production and Ca2+ buffering is needed.  Once the Ca2+ has been buffered, the 
mitochondria can bind kinesin again, and move along the axon to find the next 
area of increased activity (Saotome et al., 2008; Wang and Schwarz, 2009; 
MacAskill et al., 2009).  A simple model is that either Wlds-expressing 
mitochondria are unable to sense Ca2+ and thereby move more, or they can 
uptake the Ca2+ more quickly and therefore, spend most of the time moving in 
the cell.  Since we are interested in how Wlds functions to suppress axon 
degeneration, we decided to look at differences in the Ca2+ wave after axon 
injury.  To test whether Wlds-expressing flies are either unable to sense Ca2+ or 
can quench the signal faster, we looked at Ca2+ waves after injury in wild-type 
and Wlds-expressing open filet preparations of 3rd instar larvae.  We used Tdc2-
Gal4 driving UAS-MCD8::Cherry to visualize the axons and UAS-gCaMP3 to 
visualize the Ca2+ wave after injury.   A baseline movie of the gCaMP3 signal 
was taken before ablation, then a cherry+ axon was laser-ablated, and the movie 
continued until well after the gCaMP3 signal abated.  In wild-type animals, there 
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was a sharp peak of Ca2+ directly after injury, which slowly comes back to 
baseline.  Similar Ca2+ curves have been seen in other species both in vivo and 
in vitro after axotomy, indicating that the Ca2+ wave after injury is a conserved 
event (Ziv and Spira, 1995; George et al., 1995; Knoferle et al., 2010).  
Interestingly, in both distal and proximal segments, the peak gCaMP3 signal after 
injury in Wlds-expressing flies was less intense and was cleared faster (Fig 3-4A 
and 3-S5).  We also find that Nmnat3 has the same effect on injury-induced Ca2+ 
as Wlds, and that weakly neuroprotective molecules have an intermediate effect 
on the injury-induced Ca2+ wave (Fig 3-4B).  Once again, this correlates the axon 
protective function with the ability to dampen injury-induced Ca2+ signal.  If Wlds-
expressing flies were unable to sense Ca2+, they would most likely have a longer-
lasting signal than wild-type.  As this is not the case, we hypothesize that Wlds 
mitochondria are able to uptake and buffer the Ca2+ wave after injury more 
quickly than in wild-type.   
Conclusions 
 In this study, we show that Nmnat3 can protect at levels similar to that of 
Wlds in Drosophila olfactory neurons.  At 10 and 20 days after axotomy, the 
number of GFP+ intact axons is similar to uninjured flies, and the protective 
ability of Wlds and Nmnat3 decreases similarly at 50 days after axotomy.  We 
also show that Nmnat3, a mammalian protein, localizes to the mitochondria of 
Drosophila ORNs.  With previous findings of Wlds in the mitochondria (Yahata et 
al., 2009; T.Gillingwater, personal communication), as well as our finding that the 
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protective phenotypes of Wlds and Nmnat3 are very similar, we propose that the 
site of action is in the mitochondria. 
Through our study of mitochondria, we have described the first cell 
biological change seen in Wlds-expressing axons prior to injury, showed that this 
change in mitochondrial movement is essential to Wlds protective function, and 
hypothesize that an increase in Ca2+ buffering after injury is the mechanism of 
action.  Ca2+ buffering is known to be influenced by a negative mitochondrial 
membrane potential (Babcock et al., 1997), and increasing the negative potential 
increases mitochondrial Ca2+ uptake capacity (Tanaka et al., 2009).  The 
membrane potential is maintained through the pumping of protons out of the 
mitochondria and the activity of the electron transport chain.  Wlds could aid in 
increasing the membrane potential by increasing NAD+ inside the mitochondria, 
which could feed into the electron transport chain, making more ATP and 
decreasing the membrane potential.  Interestingly, Yahata et al., 2009, recently 
published that Nmnat3 and Wlds-expressing mitochondria show an increase in 
ATP production, supporting our model. Certainly, biochemical studies of Ca2+ 
buffering capacity in Wlds-expressing mitochondria would be key to solidify the 
model.  An increase in Ca2+ buffering and therefore a decrease of Ca2+ in the 
cytoplasm would account for both the increase in mitochondrial movement and 
the decrease in Ca2+ signal after axotomy.  High Ca2+ waves are responsible for 
apoptosis and necrosis, suggesting a common initiation signal for many types of 
death, although signaling cascades that follow can vary greatly (Celsi et al., 
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2009).  It becomes more likely then, that a Ca2+ wave could be the initiating event 
in the Wallerian degeneration cascade.  More importantly, mitochondria seem to 
be important when it comes to Ca2+ overload; in apoptosis, factors are released 
due to high Ca2+ in the mitochondria that lead to death, and in necrosis, the 
permeability transition pore is opened, most likely in response to high Ca2+, again 
leading to cell death (Celsi et al., 2009).  What remains downstream in Wallerian 
degeneration is still a mystery, but the fact that Wlds localizes to mitochondria 
and has an extremely important function there seems to point to the initiation 
factor being associated with mitochondria. 
 It is quite interesting that the initial peak of Ca2+ after axotomy is reduced 
in Wlds- and Nmnat3- expressing flies.  One possibility is the ability of Wlds-
expressing mitochondria to uptake calcium is so quick, we simply do not see the 
highest peak on the microscope in between the time it takes to ablate the axon 
and set up the recording of the image.  It is also possible that Ca2+ is unable to 
enter the cell as efficiently in Wlds- or Nmnat3- expressing flies.  A marker for 
mitochondrial Ca2+, such as mito-gCaMP3 would be helpful to address this 
question.   
The mechanism of Wlds in mitochondria may precede deficits in 
mitochondria seen in certain disease models, such as Alzheimer’s and 
Parkinson’s, which would explain why Wlds has been ineffective in protecting 
these disease models.  In these disease states, the electron transport chain is 
defective, leading to a compromised mitochondrial membrane potential, which 
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would presumably affect the calcium uptake capacity of those mitochondria.  
Since our model places Wlds upstream of the electron transport chain and 
mitochondrial potential, any deficits downstream would not allow Wlds to protect 
the axons.  Thus, it is imperative that the role of mitochondria in 
neurodegeneration be fully elucidated to find potential therapeutic targets.   
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Materials and Methods 
 
Injury protocol 
Flies were anesthetized on CO2 pads and their 3rd antennal segments removed.  
Drosophila were kept at 25°C for 5, 10, 15, 20, or 50 days post ablation.  All 
uninjured flies were dissected one week post-eclosion unless noted as age 
matched. 
 
Drosophila stocks and transgenics 
The following stocks were used: OR22a-Gal4 (B.Dickson, Vienna), pUAST-
mcd8::GFP, p{UAS-mitoGFP.AP}2, p{UAS-mitoGFP.AP}3, p{Tdc2-Gal4.C}2, 
p{UAS-CD2-RFP} Bloomington), MiroSD32/TM6, MiroSD26/TM6 (Guo et al., 2005), 
p(UAS-Myc-Miro) (K. Zinsmaier, University of Arizona), UAS-gCaMP3 (L. Looger, 
JFRC), pUAST-Wlds, pUAST-N16::Nmnat1, pUAST-Nmnat1, pUAST-
Nmnat1dead, pUAST-Wlds-dead, pUAST-Nmnat3, pUAST-Nmnat2, and pUAST-
ΔN16-Wlds (Avery et al., 2009) 
 
pUAST-Nmnat2::myc was made by PCR amplifying amino acids 1-306 of mouse 
Nmnat2, cDNA clone BC098007 (Openbiosystems), with NotI sites at both ends, 
excluding the stop codon at 3’ end.  It was the cloned into pUAST-myc vector 
and checked for correct orientation. 
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pUAST-Nmnat3::myc was made by PCR amplifying amino acids 1-244 of mouse 
Nmnat3, cDNA clone BC092086 (Openbiosystems), with NotI sites at both ends, 
excluding the stop codon at 3’ end.  It was then cloned into the pUAST-myc 
vector and checked for correct orientation. 
 
pUAST-mcd8::mcherry was made by PCR amplifying 726bp of mCherry PCR 
from pKR5-mCherry.  EcoRI site was added to the 5’, and XbaI added to 3’ after 
stop codon and then it was cloned into the EcoRI/Xba site of pUAST. 
 
Immunolabeling and Confocal Microscopy 
Standard methods were used for dissection, fixation, and antibody labeling of the 
Drosophila adult brain (Voshall et al., 2000).  Primary antibodies were used at the 
following dilutions: mouse anti-myc (9E10, Covance Innovative Antibodies) 
1:1000.  Secondary antibodies (Jackson Immunoresearch) were used at 1:200.  
Images were then mounted in Vectashield, and viewed with a Zeiss Imager M10 
spinning disc confocal.  
 
Quantification 
For adult brain axotomy, Z stacks were compressed with ImageJ software, and 
intact GFP+ axons were counted.  For live imaging, 4D movies were compressed 
to 2D along the Z axis.  The number of GFP+ mitochondria were counted in the 
first frame of the movie, and stationary mitochondria were counted throughout 
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the timeframe.  For gCaMP3 quantification, 4D movies were compressed to 2D, 
and average intensity from an uncut nerve was subtracted from the average 
intensity of a cut nerve (either distal or proximal) at each timepoint.  We then 
subtracted from this number the average intensity from the 5 minute baseline 
movie.   
 
Live Imaging 
3rd instar wandering larvae were fillet-prepped in HL6 (MacLeod et, al., 2002), 
and glued to the live imaging chamber with Surgi-Lock 2oc (Healthypets.com).  
Starting near the ventral nerve cord, 3 sections of the nerves were imaged in the 
larva for 5 minutes each. 
 
Kymographs 
2D movies were aligned with Image J plugin “align slice”.  The Image J plugin 
“multiple kymograph” was then used to create the kymograph. 
 
Laser ablation 
3rd instar wandering larvae were fillet-prepped in HL6 (MacLeod et al., 2002) and 
glued to a perfusion chamber (Warner Instruments, RC-30) with Surgi-Lock 2oc 
(Healthypets.com).  A baseline movie ran for 5 minutes, then a small section of 1 
nerve was laser ablated with a 435 wavelength laser at 70% power.  Movies 
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were then collected every 5 minutes afterwards for a total of 20 minutes.  Larvae 
were washed with HL6 in between each 5 minute movie.  
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Fig 3-1 
	   106	  
Fig 3-1.  Nmnat3 is mitochondrial in Drosophila ORNs and protects as well 
as WldS.  (A) Mitochondrial GFP (top panel) colocalizes with Nmnat3 myc tag 
staining (middle panel).  The merge is shown in the bottom panel.  (B) At 10, 20, 
and 50 days post axotomy, the level of axon protection afforded by Nmnat3 is no 
different from that of WldS. 
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Fig. 3-2 
Fig. 3-2.  WldS and other strongly neuroprotective molecules show a 
decrease in stationary mitochondria.  (A) Representative confocal image of 
mitochondria (mito-GFP, top panel) and mCherry+ motorneurons (middle panel) 
used for imaging of mitochondrial movement.  (B) Representative kymographs 
from control and WldS-expressing larvae.  Straight lines denote stationary 
mitochondria; diagonal lines denote moving mitochondria.  (C) Quantification of 
the number of stationary mitochondria per nerve per 5 minute period (n>10, * 
p<.05, *** p<.001).    
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Fig. 3-3 
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Fig. 3-3.  Suppression of mitochondria movement suppresses WldS 
protection of severed axons.  (A) Quantification of mitochondria movement in 
heterozygous miro alleles expressing WldS.  Miro heterozygotes with WldS and 
overexpression of Miro increase the number of stationary mitochondria in 3rd 
instar larvae compared to both control and WldS-expressing mitochondria.  (B) 
Quantification of the effect of miro heterozygous alleles or overexpression of Miro 
on WldS-mediated axon protection.  Miro reduces the efficacy of WldS severed 
axon protection.  (C) Representative images of WldS, MiroSD32/WldS, and UAS-
myc-Miro at 0, 5, 15, and 30 days post axotomy.  Note the appearance of blebs 
on the axons with the Miro allele and the overall decrease in axon integrity 
compared to WldS alone.  (n>10, **p<.01, ***p<.001) 
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Fig. 3-4 
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Fig. 3-4.  WldS and Nmnat3 decrease the intensity and duration of gCaMP3 
signal post-axotomy.  (A) Time course of gCaMP3 signal in the distal portion of 
the axon post axotomy in control, WldS-, and Nmnat1dead-expressing 3rd instar 
larvae.  (B) gCaMP3 signal intensity peak after laser-induced axotomy.  (C) Time 
course of gCaMP3 signal in the distal portion of the axon post axotomy in control, 
Nmnat1-, Nmnat3-, and WldS-dead-expressing 3rd instar larvae.  (D) Recovery time 
of the gCaMP3 signal to ½ its peak.  (n=5, *p<.05, **p<.01, ***p<.001) 
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Fig. 3-S1 
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Fig. 3-S1.  Nmnat2 localizes to the cytoplasm of Drosophila ORNs and 
cannot protect severed ORNs.  (A) Mito-GFP (top panel) does not colocalize 
with the Nmnat2 myc antibody stain (middle panel.  Bottom panel shows merge.  
(B) Quantification of control and Nmnat2 GFP+ intact axons at 0, 3, and 5 days 
after injury. 
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Fig 3-S2 
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Fig 3-S2.  Number and size of mitochondria are not changed amongst 
genotypes.  (A) Number of mitochondria per µm.  Only WldS shows a slight 
increase in size compared with control.  (B) Standard distribution of the mean 
mitochondria size.  (n>10, *p<.05) 
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Fig. 3-S3 
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Fig. 3-S3.  Miro heterozygous alleles and Miro overexpression do not affect 
development or degeneration.  (A) Quantification of miro heterozygous alleles 
and Miro overexpression before and 5 days post-injury.  Miro heterozygous 
alleles and Miro overexpression do not differ from controls in number of axons 
present before and 5 days post-axotomy. 
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Fig. 3-S4 
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Fig. 3-S4.  Miro heterozygous alleles and overexpression alone increase 
stationary mitochondria and the overexpression decreases the number of 
mitochondria present.  (A) Quantification of mitochondrial movement over 5 
minutes in 3rd instar larvae.  As has been previously reported, miro heterozygous 
alleles and Miro overexpression increases the number of stationary mitochondria.  
(B) Number of mitochondria per µm is only changed in the Miro overexpression 
as has been reported.  (Russo et al., 2009) (n>5, **p<.01, ***p<.001) 
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Fig 3-S5 
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Fig 3-S5.  Proximal gCaMP3 signal after injury decreases in WldS and 
Nmnat3.  (A) Time course of gCaMP3 signal in the proximal section of 3rd instar 
larval axons post laser-ablation.  (B) Peak gCaMP3 intensity directly after 
axotomy.  (C) Recovery time of gCaMP3 signal to ½ peak after injury. 
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Chapter IV:  
A forward genetic screen to identify new genes involved 
in axon degeneration 
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Introduction 
Augustus Waller’s first observation of axon degeneration in 1850 reported 
that after a short period of latency, an axon rapidly fragmented and was cleared 
from its environment (Waller, 1850).  The fact that axons were able to remain 
intact for a latent period followed by degeneration lead researchers to believe 
that it was a passive process of wasting away, occurring simply due to the lack of 
nutrients being delivered to the severed axon.  However, the discovery of the 
Wlds spontaneous mouse mutant began to challenge the notion that axon 
degeneration is a passive process.  In these mice, axons can survive and 
function about 10-fold longer than wild-type axons, and further studies have 
shown the same is true in rat and Drosophila (Lunn et al., 1989; Adalbert et al., 
2005; MacDonald et al., 2006).  Because axon degeneration can be delayed, the 
idea emerged that Wallerian degeneration is an active process akin to apoptosis.  
However, the Wlds mutant is a gain-of-function mutation that protects in an 
overexpression manner, perhaps by enhancing normal cellular function.  
Therefore, this molecule still does not definitively show that axon degeneration is 
an active process.   
To uncover genes involved in a pathway of axon degeneration, we have 
initiated a forward genetic screen.  My part specifically was in dissecting and 
screening about half of the lines screened to this point.  If loss of a gene prevents 
an axon from degenerating, that indicates there is a pathway of degeneration that 
can be inhibited, and Wallerian degeneration is, indeed, an active process.  Here, 
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I describe the forward genetic screen and the classes of mutants that have been 
identified.  I also show we have discovered the identity of one of those genes 
involved in Wallerian degeneration. 
 
Results 
 We generated ~3,000 ethyl methane sulfonate (EMS)-mutated lines, 
selecting for mutations on the 3rd chromosome only.  The lines were set up such 
that if the mutation was lethal, we could use mosaic analysis with a cell 
repressible marker (MARCM) to get homozygous mutants in the ORNs (Fig 4-1; 
Lee and Luo, 2001).  We unilaterally ablated Drosophila antennae so that one 
side served as an uninjured control, and assayed for presence of GFP+ material 
7 days after ablation.  During the initial screen, we retain lines that we consider 
potential hits, with 2 out of 3 brains from the line showing an increase in GFP+ 
material 7 days after ablation.  We then run the potential hits through a 2nd 
screening, where we repeat the ablation to confirm the hit.  Three classes of 
interest emerged from the screen: (1) Viable mutants with axon fragments 
present at 7 days after axotomy; (2) Lethal mutants with axon fragments present 
at 7 days after axotomy; and (3) Lethal mutants with intact axons present at 7 
days after axotomy (Fig 4-2). 
 Viable mutants with axon fragments present at 7 days after axotomy 
represent either a delay in degeneration or a delay in the clearance of 
degenerated axons.  Because these mutants are viable, we do not know which 
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cell type is responsible for the phenotype during the initial screen.  To test 
whether the gene is neuronal or glia in nature, we make MARCM clones of the 
mutants within either the neurons or glia specifically.  For example, if the gene is 
acting within the neurons, the phenotype of increased GFP+ material 7 days after 
ablation will remain when mutant neuronal clones are generated.  Although we 
have several mutants within this category, we have yet to identify any of the 
genes. 
 Lethal mutations that result in fragmented GFP+ axonal material present 7 
days after axotomy represent either a delay in degeneration within the neuron or 
a mutation in a signaling mechanism from neurons to glia, which leads to glial 
clearance of the debris.  Because they are lethal, we know all of these mutations 
are within the neuron, as we use a neuronal driver to make the MARCM clones.  
We only have few mutants in this class, but they could possibly link the process 
of neuronal degeneration to clearance by glia. 
 The final class of mutants is lethal, with intact GFP+ axons remaining at 7 
days post axotomy.  This class represents mutations within the neuron that delay 
Wallerian degeneration.  We found three very strong mutants in this class 
reminiscent of Wlds (Fig 4-3A).  At least one of the mutants can protect axons 30 
days after injury; the other mutants have not been tested at this timepoint yet.  
Interestingly, we found that all three of these mutants failed to complement each 
other for both lethality and the phenotype of intact axons after ablation, 
suggesting that they are all alleles of the same gene.  Each mutant was also 
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crossed to the 3rd chromosome mini deficiency kit (Bloomington), and screened 
for failure to complement lethality.  All 3 mutants failed to complement lethality of 
mini deficiencies for the same region on 3L near chromosomal location 66B5, 
narrowing the location of the mutation to 14 genes.  Finally, I found that all three 
mutant phenotypes were recessive, as no GFP+ intact axons were observed 
when the heterozygous flies were axotomized. 
EMS mutagenesis in the past has included the daunting task of finding the 
mutant gene after a phenotype of interest has emerged.  However, with the new 
technology of deep sequencing, it is possible to sequence the entire Drosophila 
genome in a very short period of time.  Due to our isolation of mutant 3rd 
chromosomes, we already knew that our genes of interest were on the 3rd 
chromosome.  We also knew we had 3 independently isolated alleles of the 
gene, and that they failed to complement a small number of genes from the mini 
deficiency kit.  Therefore, through the process of deep sequencing, we were able 
to find our gene of interest very quickly.  Stephan Zuchner (University of Miami) 
compared the DNA sequences of the 3 mutant lines to an isogenized control line.  
He looked for short nucleotide polymorphisms in exons that were present in the 
same gene for all 3 mutant lines, and which would result in a non-functional 
protein.  Because the complementation crosses had narrowed the region of 
interest, he concentrated his analysis to those 14 genes.  All 3 alleles were found 
to be early stop codons in the gene Ect-4 (Fig 4-3B).  Jeannette Osterloh will 
	   128	  
continue to study this gene and try to find the mechanism or pathway through 
which Ect-4 acts to prevent axon degeneration. 
 
Conclusions 
Through an EMS-induced forward genetic screen, we have uncovered 3 
classes of mutants of interest: viables with axon fragments remaining at 7 days 
post axotomy, lethals with axon fragments remaining at 7 days post axotomy, 
and lethals with intact axons remaining at 7 days post axotomy.  In the work of 
one screen, we now have genes which may be found in glia to regulate 
clearance of axons, may be in neurons to communicate to glia to clear axonal 
debris, and genes that suppress Wallerian degeneration in the axon.  In this 
aspect, the screen has been very fruitful for a variety of projects on-going in the 
lab.  In the years to come, these genes will be identified through 
complementation and deep sequencing, and hopefully, new genes and pathways 
will emerge.  The most exciting mutant to emerge from the screen is Ect-4, which 
definitively shows that Wallerian degeneration is an active process. 
Although not a lot is known about Drosophila Ect-4, there have been 
papers published on its mammalian homologue, MyD88-5 or SARM, and its C. 
elegans homologue, TIR-1.  Interestingly, MyD88-5 has been found to be 
preferentially expressed in neurons and is localized to the outer membrane of 
mitochondria as well as microtubules (Kim et al., 2007).  The exact mechanism of 
Ect-4 in Wallerian degeneration is unknown, but some clues have come from the 
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studies in the mouse.  Kim et al. discovered that MyD88-5 binds JNK3 both in 
vitro and in vivo (2007).  MyD88-5 promotes the relocalization of JNK3 from the 
cytoplasm and plasma membrane to the mitochondria (Kim et al., 2007).  JNK3 
has been reported to be involved in neuronal death following ischemia, making 
this pathway a very intriguing possibility for involvement in Wallerian 
degeneration as well.  JNK3 is also reported to be downstream of, and activated 
by, CamKII in apoptosis.  This draws another intriguing parallel between 
apoptosis and Wallerian degeneration, as CamKII is activated by Ca2+, which is 
involved in both apoptosis and axon death signaling.  Thus, a model could arise 
whereby an increase in Ca2+ activates CamKII, which in turn activates JNK3 that 
is bound to MyD88-5 at the mitochondrial membrane, and leads to cell death or 
Wallerian degeneration through the mitochondria.  In the absence of MyD88-5 
(Ect-4), JNK3 cannot localize to the mitochondria and therefore, the Wallerian 
death pathway cannot be initiated.  MyD88-5 was also shown to have an 
involvement in neuronal cell death following oxygen-glucose deprivation, as 
knockouts of MyD88-5 showed a decrease in cell death (Kim et al., 2007).  It will 
be imperative to study whether JNK3 is involved in Wallerian degeneration and to 
identify components both up- and downstream of Ect-4 after axotomy. 
In conclusion, our work has identified the first mutant gene that blocks 
Wallerian degeneration thereby classifying Wallerian degeneration as an active 
pathway.  Further work needs to be done to identify the pathway that leads to 
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degeneration and all of the genes discovered will represent possible therapeutic 
targets for neurodegeneration. 
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Materials and Methods 
Fly stocks used 
The following stock were used: OR22a-Gal4 (B. Dickson, Vienna); pUAST-
MCD8::GFP; FRT2A, tub-Gal80; FRT82B, tub-Gal80; ey-flp, UAS-mCD8::GFP; 
mini Df kit of 3rd chromosome (Bloomington); and FRT2X (T. Lee, Janelia 
Farms). 
EMS mutagenesis 
Adult male Drosophila were starved for at least 5 hours prior to mutagenesis and 
kept at 25°C.  About 100 males were placed in a bottle with about 25 mM EMS 
solution soaked into Kimwipes.  To prepare the 25mM EMS, 63µL of EMS was 
added to 25mL of 1% sucrose, and then 5mL of this solution was added to empty 
bottles.  Males were remained in the EMS bottle overnight, and were transferred 
to clean bottles with normal food the following morning.  Males were allowed to 
clean themselves all day before being transferred to another bottle with non-EMS 
treated virgins.  
Injury protocol 
Flies were anesthetized on CO2 pads and the left 3rd antennal segment was 
removed.  The right antenna was kept intact as an internal control.  Flies were 
ablated at least 1 week post-eclosion, and dissected 7 days after ablation.  
Brains were then imaged with confocal microscopy. 
Confocal Imaging 
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Standard methods were used for dissection and fixation labeling of the 
Drosophila adult brain (Voshall et al., 2000).  Brains were then mounted in 75% 
glycerol and viewed with either a Zeiss Imager M10 spinning disc confocal or a 
Axioskop2 LSM 5 Pascal point scanning confocal.  Lines with a GFP+ axonal 
material present 7 days after axotomy in 2 out of 3 brains were kept for 
confirmation and analysis.  For confirmation, the lines were retested for GFP+ 
axonal material present 7 days after axotomy, and after the phenotype was 
confirmed, the lines were tested for complementation and DNA was sent for deep 
sequencing. 
Complementation assay 
The Exelixis mini deficiency kit of chromosome 3 was used in our 
complementation assay.  We screened for deficiencies which failed to 
complement the lethality of the mutant lines of interest.   
Deep sequencing 
Deep sequencing of the Drosophila genomes of interest were performed by 
Stephan Zuchner, PhD, of the University of Miami.  DNA from our background 
isogenized strain of 22a-Gal4, UAS-MCD8::GFP/ CyO; FRT2X was compared to 
the DNA of our mutant strains.  Dr. Zuchner then looked for single nucleotide 
polymorphisms in exons in the region of interest  on 3L narrowed down by the 
complementation crosses and found mutations that led to early stop codons. 
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EMS fed to: 
22a-Gal4, UAS-MCD8::GFP ; FRT2X 
              CyO                           FRT2X 
100 males to 150 virgins: 
22a-Gal4, UAS-MCD8::GFP ; FRT2X*      X  22a-Gal4, UAS-MCD8::GFP ;  Dr 
              CyO                            FRT2X                                 CyO                  TM3 
 
Single male to 3 virgins: 
22a-Gal4, UAS-MCD8::GFP ; FRT2X*      X   22a-Gal4, UAS-MCD8::GFP ; Dr 
              CyO                             TM3                            CyO                          TM3 
 
 
22a-Gal4, UAS-MCD8::GFP ; FRT2X* 
              CyO                             TM3          Self-cross to make stocks 
 
If viable, test homozygous stock; If lethal: 
22a-Gal4,UAS-MCD8::GFP;FRT2X*   ey-flp,UAS-MCD8::GFP;;FRT2A,tub-Gal80 
             CyO                          TM3     X            FM7                             TM3 
 
For other chromosome, use FRT82B, tub-Gal80 
Fig 4-1 
 
 
	   134	  
Fig. 4-1 The cross schematic for creation of EMS-mutagenized stocks. 
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Fig 4-2 
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Fig 4-2.  Three classes of mutants of interest emerged from the screen.  (A) 
Representative image of a viable mutant with axon fragments remaining.  (B) 
Representative image of a lethal mutant with axon fragments remaining.  (C) 
Representative image of a lethal mutant with intact axons remaining, reminiscent 
of WldS.  In all cases, the left side is uninjured and the right side is injured.  
Images are of 7 days post-axotomy. 
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Fig 4-3 
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Fig 4-3.  Ect4 mutants protect axons after axotomy.  (A) Representative 
images of control and 3 separate alleles of Ect4 (896, 4621, and 4705).  Left side 
is uninjured and right side is injured, imaged 7 days post-axotomy.  (B)  
Locations of the Ect4 mutations in all 3 alleles.  All resulted in an early stop 
codon in an exon shared by all Ect4 isoforms. 
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Chapter V: 
Conclusions 
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 The work presented in this thesis has focused on: (1) the mechanisms of 
axon degeneration through the study of the novel fusion protein, Wlds, (2) the 
function of Wlds within the mitochondria, and (3) the discovery of a gene involved 
in Wallerian degeneration.  The second chapter of this thesis identified the 
domains of Wlds that are necessary and sufficient for protection of severed 
axons, highlighted a role for VCP/TER94 in Wlds-mediated protection, and began 
to suggest that subcellular localization of Nmnat is what determines protection.  
The third chapter focused on a role for mitochondria in Wlds-mediated axon 
protection, and found that mitochondria show an increase in movement before 
injury and a decrease in Ca2+ post-injury in Drosophila larval axons.  The fourth 
chapter in this thesis showed that Wallerian degeneration is an active process, 
which can be prevented by a loss of Ect-4 protein, a proposed mitochondrial 
protein based on its mammalian homology. 
 
N16 fused to Nmnat1 phenocopies Wlds 
 My first goal was to narrow down the domains of Wlds that contribute to 
the protection of severed axons.  We showed for the first time, in vivo, that 
mammalian Nmnat1 can protect severed Drosophila axons, however, this 
protection is always lower than that of full-length Wlds. We also found that 
enzymatic activity of Wlds and Nmnat1 is necessary for protective function, a 
finding that has been repeated in the mammalian literature as well (Conforti et 
al., 2009; Sasaki et al., 2009; Yahata et al., 2009).  Although Nmnat1 with 
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enzymatic ability accounts for the majority of the axon protection seen with Wlds, 
addition of some N-terminal portion boosts Nmnat1 protection to that of Wlds 
since the level of protection afforded by Nmnat1 is always lower than that of 
Wlds. 
 Clues as to which portion of the N-terminus of Wlds is important for axonal 
protection came from the Laser et al. study that found the first 16 amino acids of 
Wlds bind to VCP, a molecule with several cellular functions.  The authors 
thought that VCP’s interaction with the UPS was important in regards to Wlds 
(2006).  We found that the first 16 amino acids (N16) of Wlds are important for 
Wlds protective function in Drosophila ORNs.  When we deleted the first 16 
amino acids, we found that Wlds protection of severed axons was weakened.  
Reciprocally, when we fused N16 to Nmnat1, we found that it completely 
recapitulated the Wlds phenotype.  Conforti et al. found that removing N16 from 
Wlds resulted in little to no axonal protection in the mouse, supporting our work in 
the fly (2009).  We then tested the requirement of VCP/TER94 in axonal 
protection by using RNAi to knock down VCP/TER94 specifically in the olfactory 
neurons we assay for protection.  When we expressed VCP/TER94 RNAi with 
Wlds, we found that axonal protection after axotomy decreased, indicating that 
VCP/TER94 is involved with the N-terminal protective boost that N16 gives to 
Nmnat1.  Conforti et al. found that if N16 of Wlds is replaced with a different 
VCP/TER94 binding site in the mouse, this molecule is able to protect as well as 
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normal Wlds, again indicating that VCP/TER94 is important for Wlds protection 
(2009). 
 Interestingly, when we knocked down other UPS components known to 
form a complex with VCP/TER94, we found no effect on Wlds protection.  At the 
time we thought that perhaps VCP/TER94 was acting through one of its many 
other cellular functions to boost Nmnat1 protection.  However, now that we think 
the site of Wlds action is in the mitochondria, we believe that the purpose of 
VCP/TER94 binding is actually to aid in the relocalization of Nmnat1 from the 
nucleus to the mitochondria.  To further support that there is not a role for 
VCP/TER94 beyond its physical interaction with WldS, Beirowski et al. has tested 
a Wlds in which VCP binding is weakened.  This altered molecule protects as well 
as normal Wlds (2010).  Whatever weak binding remains is likely enough to 
relocalize Wlds to the mitochondria, and therefore, high protective levels remain.      
 
Nmnat targeted to mitochondria protects as well as Wlds 
 Although Wlds predominantly localized to the nucleus, we wondered if its 
nuclear localization was necessary, or if Nmnat or Wlds targeted to other portions 
of the cell could protect axons after injury as well.  The first clue that the nucleus 
is not the site of action came from over-expressing Nmnat1.  We knew from our 
first study that the majority of Nmnat1 is expressed in Drosophila nuclei, and we 
also knew that Nmnat1 could not protect as well as Wlds.  So we decided to test 
if plasma membrane-tethered WldS, NADS (Drosophila NAD-synthesizing 
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molecule), or 2 other mammalian Nmnats (Nmnat2 and Nmnat3) could protect 
severed axons.  Tagging Wlds to the plasma membrane with mCD8 rendered 
Wlds unable to protect severed axons.  It is important to note that we do not know 
if the Nmnat1 of membrane-tethered Wlds was able to form hexamers essential 
for Nmnat1 function of NAD synthesis, which could account for its inability to 
protect.  However, this result led us to believe that localization of Wlds was 
important for its suppression of axon degeneration.  We also wanted to test if any 
NAD-synthesizing molecule could protect severed axons, or if there was 
something special about Nmnat.  We drove NADS in ORNs and found that it 
offered no axon protection 5 days post injury.  We also added the N16 domain to 
NADS, but found no protection offered by this molecule, indicating there is 
something unique about Nmnat.  Therefore, we conclude that Nmnat is 
necessary for axon protection after injury, and that its localization is important. 
 From the mammalian literature, we knew that there were 3 different 
Nmnats.  Nmnat1 is predominantly nuclear, Nmnat2 is either Golgi-associated or 
cytoplasmic, and Nmnat3 is mitochondrial (Sasaki et al., 2006).  As stated above, 
Nmnat1 can protect Drosophila severed axons, but not as well as Wlds.  We find 
that Nmnat2 cannot protect severed axons in vivo 5 days post injury, though 2 
studies in mammals have reported slight protection in vitro (Yan et al., 2009; 
Gilley and Coleman, 2010).  It still remains an open question if Nmnat2 can 
protect in vivo in mammals.  It has also been reported that Nmnat2 has a short 
half-life, which could account for the lack of protection seen in vivo in Drosophila 
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axons (Gilley and Coleman, 2010).  To test if Nmnat2 protein is degraded at the 
5 day timepoint thus accounting for the lack of axon protection seen, we 
expressed Nmnat2::myc with Wlds.  We found that Nmnat2::myc is still 
expressed in axons 5 days post-injury.  This result indicates that Nmnat2 is not 
degraded within 5 days post-injury and thus, a shortened half-life cannot account 
for the lack of axon protection in Drosophila.  We propose instead, that the lack 
of protection of Nmnat2 is due to its localization. 
 Mitochondrial localization appears to be imperative for Nmnat-mediated 
severed axon protection in Drosophila, as Nmnat3, a mitochondrial protein can 
protect as well as Wlds.  We have tested the ability of Nmnat3 to protect severed 
axons for as long as 50 days post-axotomy and found in all cases, Nmnat3 
protects as well as Wlds.  Around the same time we discovered this result, Wlds 
was reported to localize to mitochondria and Nmnat3 was found to be the only 
Nmnat that could protect in the mouse when over-expressed (Yahata et al, 
2009).  It was also found that if Wlds is forced out of the nucleus, the level of 
axon protection actually increases, and cytoplasmic Wlds fractionates 
predominantly with mitochondria (Beirowski et al., 2009).  All of this evidence 
points to a role in mitochondria for Wlds, which has fueled our subsequent study.    
 
Mitochondria are more motile when neuroprotective molecules are present 
 Evidence was accumulating which pointed to mitochondria as the potential 
site of Wlds action.  Therefore, we decided to study mitochondria in a Wlds-
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expressing axon.  We used a 3rd instar larval fillet preparation to examine 
mitochondria in a live animal.  We found that mitochondria in Wlds-expressing 
larvae are more motile than those in wild-type.  What is more interesting, the 
amount of neuroprotection afforded by several molecules correlated perfectly 
with the increase in motile mitochondria.  For instance, Nmnat1, ΔN16-Wlds, and 
Wlds-dead, which all show a weak protection at 5 days post axotomy, all showed a 
slight increase in mitochondrial movement.  Molecules which show strong 
protection of severed axons at 5 days post injury, such as Wlds, Nmnat3, and 
N16::Nmnat1, all had a great increase in mitochondrial motility.  The strong 
correlation of mitochondrial motility and axon protection led us to postulate that 
mitochondrial motility is necessary for axon protection.   
 To test this hypothesis directly, we used heterozygous mutants of miro, 
which are known to decrease mitochondrial movement without disrupting the 
number of mitochondria present in the neuron (Russo et al., 2009).  We first 
found the heterozygous mutants of miro were able to suppress the increase in 
mitochondrial motility in axons expressing Wlds.  Upon suppressing mitochondrial 
motility, we found that we could also suppress Wlds axon protection, indicating 
that mitochondrial motility is critical for Wlds-mediated protection.  In this study, 
we uncovered the first cell biological difference prior to injury in Wlds-expressing 
axons, and showed that the difference in mitochondrial motility is necessary for 
Wlds function. 
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 This finding that an increase in mitochondrial motility boosts protection of 
Wlds is very intriguing, as many neurological diseases report a deficit in 
mitochondrial trafficking.  Deletion of Mfn2, a gene involved in mitochondrial 
fusion, is a mouse model of Charcot Marie Tooth disease 2A (CMT2A).  
Recently, it was reported that these mice show a decrease in mitochondrial 
transport, but other organelles remain unaffected (Misko et al., 2010).  The 
decrease in mitochondrial transport seems unrelated to Mfn2’s mitochondrial 
fusion function as another gene which affects mitochondrial function does not 
disrupt transport.  It has also been reported that mitochondria accumulate and 
stop in amyloid precursor protein+ axonal swellings produced in a mouse model 
of Alzheimer’s disease (Adalbert et al., 2008).  Whether the impairment of 
mitochondrial trafficking is causal to Alzheimer’s disease remains to be seen, 
however both studies highlight the importance of maintaining proper 
mitochondrial trafficking to sustain a healthy neuron. 
 
Injury-induced Ca2+ waves are decreased in the presence of 
neuroprotective molecules Wlds and Nmnat3 
 Discovering an increase in mitochondrial motility in Wlds-expressing axons 
is an exciting finding, but it left the question open of why do the mitochondria 
move more.  Moreover, why do mitochondria need to move in the first place?  
Axons are long structures (in some animals a length of many feet) that need a 
constant supply of energy to aid in synaptic transmission.  The mitochondria 
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travel along the axon to produce ATP at hot spots of high-energy consumption.  
A constant delivery of mitochondria down the axon ensures that new, healthy 
mitochondria are able to meet the high-energy demands of the axon.  The 
movement also ensures that the entire axon is monitored for areas of high 
calcium and low ATP.  As mitochondria age, they becomes less able to produce 
high amounts of energy, and are either transported back to the cell body to be 
degraded, or undergo mitophagy within the axon (Cal and Sheng, 2009).   
 Mitochondria also have the ability to buffer large amounts of calcium.  
Calcium actually controls mitochondrial movement, in that as the amount of 
calcium increases, the number of moving mitochondria decreases (Saotome et 
al., 2009).  Mitochondrial movement resumes once mitochondria have taken up 
and buffered calcium from the cytosol.  We hypothesized that the amount of 
calcium present in the cytoplasm is reduced in Wlds-expressing axons, which 
would lead to an increase in mitochondrial movement.  We found that after 
axotomy there is a spike in calcium in the axon, as seen by an increase in 
gCaMP3 fluorescence.  Interestingly, when we express Wlds or Nmnat3, we find 
this large increase in gCaMP3 fluorescence is greatly dampened, and the time it 
takes the gCaMP3 signal to return to baseline is quicker than in wild type.  We 
also found that the weakly neuroprotective molecules, Nmnat1 and Wlds-dead, 
slightly decreased the gCaMP3 signal after axotomy, correlating the amount of 
neuroprotection with a decrease in gCaMP3 signal after injury.  These data 
suggest that calcium buffering in Wlds-expressing axons is increased as the 
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gCaMP3 signal is decrease, but this needs to be confirmed by studying the Ca2+ 
buffering capacity of mitochondria expressing Wlds through biochemical means. 
 How could Wlds increase the calcium buffering capacity of mitochondria?  
It is known that calcium buffering is controlled by negative membrane potential in 
mitochondria, amongst other factors (Babcock et al., 2007).  It is possible that a 
local increase in NAD+ production in the mitochondria by Nmnat1 could lead to 
more ATP production.  ATP production maintains a negative mitochondrial 
membrane potential by pumping protons out of the mitochondria.  Interestingly, it 
has been recently noted that both Wlds- and Nmnat3-expressing mitochondria 
produce more ATP (Yahata et al., 2009), fitting in with our model (Fig. 5-1).  With 
hyperpolarized mitochondria, calcium buffering is increased.  If calcium buffering 
is increased, the amount of calcium within the cytosol is decreased, and 
therefore, the mitochondria exhibit increased movement.  One could also imagine 
that an increase in movement would allow the mitochondria to cover more space 
faster, thereby again increasing the amount of calcium buffering that can occur.  
Once again, a study of mitochondrial bioenergetics of Wlds-expressing 
mitochondria can confirm this model, and plans are in the works to collaborate 
with James Geddes, Ph.D. (University of Kentucky) to test our hypothesis.  Our 
model assumes that Ca2+ is most likely a trigger for axonal death.  Although this 
has been shown in the case of nerve cut (Knoferle et al., 2010; Ziv and Spira, 
1995; and George et al., 1995), it remains to be seen if Ca2+ is a death signal in 
the case of axonal transport blockade and protein synthesis inhibition, both of 
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which are sensitive to Wlds.  It seems highly likely, as Ca2+ increase triggers cell 
death in a variety of other instances, but until it is proven in other types of axonal 
degeneration, the proposed model may be limited to axonal cut. 
 
Ect-4, a mitochondria protein, is involved in Wallerian degeneration 
  In the final study of this thesis, many members of the lab and I performed 
an EMS-based forward genetic screen.  We aimed to identify mutants that could 
disrupt glial clearance of axons, disrupt neuron to glia signaling to clear axonal 
debris, and disrupt Wallerian degeneration itself.  We have since confirmed 
mutants of all three classes, which will provide years of studies to come from the 
lab.  What is most relevant to my work, however, is the discovery of a gene that 
blocks Wallerian degeneration.  Previously, the only evidence that Wallerian 
degeneration is an active process came from the Wlds protein itself.  Although 
Wlds has been a great tool to discover how to prevent an axon from 
degenerating, its nature as a gain-of-function mutation that is over-expressed to 
prevent axon degeneration does not address whether Wallerian degeneration is 
an active pathway.  The discovery of Ect-4, however, definitively shows that 
Wallerian degeneration is an active process, as mutation of this gene blocks 
degeneration in Drosophila neurons for at least 30 days post-injury. 
 The mammalian homologue of Drosophila Ect-4 to date, MyD88-5 or 
SARM, offer some clues as to its function.  MyD88-5 is localized to mitochondria 
and microtubules specifically in neurons.  Part of its function seems to be in 
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binding JNK3 to relocalize JNK3 to the mitochondria.  JNK3 and MyD88-5 have 
been shown to be involved excitotoxic neuronal death, and are thought to act 
through the mitochondria to induce cell death (Kim et al., 2007).  Further studies 
are being done by Jeannette Osterloh in the lab to uncover the role of Ect-4 in 
Wallerian degeneration.   
 
Mitochondria and neurodegeneration   
 The overall theme of this thesis is mitochondria are important in Wallerian 
degeneration.  Whether they are the source of the death pathway or simply 
upstream in Wallerian degeneration remains to be seen, but certainly changing 
the properties of mitochondrial movement or function can affect axonal death.  
Many studies are showing evidence of mitochondria dysregulation in many 
neurological diseases.  For instance, impairment in the respiratory complex I is 
an early change detected in sporadic and familial Parkinson’s disease (Bueler, 
2009).  Mutations in mitofusin2 cause mitochondria transport defects that are 
thought to be a causal event in Charcot-Marie Tooth disease 2A (CMT2A) (Chen 
and Chan, 2009).  In Alzheimer’s disease, decreased cytochrome c oxidase 
activity, increased reactive oxygen species, and abnormal mitochondrial 
morphology have been detected (Celsi et al., 2009).  Finally, in Huntington’s 
disease, complex II, III, and IV activity is reduced.  It has also been reported that 
mutant huntingtin can open the permeability transition pore of mitochondria, 
which results in the collapse of the mitochondria membrane potential, and 
	   151	  
eventual cell death (Celsi et al., 2009).  The only disease in this list that Wlds can 
protect against is CMT2A.  Taking our model into account, the dysfuction in 
mitochondrial movement seen in CMT2A could be overcome with Wlds.  In the 
cases of Alzheimer’s, Parkinson’s, and Huntington’s disease, all have 
dysfunctions that would result in alteration of the membrane potential, which is 
most likely downstream of where Wlds can act.  So no matter how much NAD+ is 
produced in the mitochondria, if the electron transport chain is dysfunctional, the 
membrane potential cannot be hyperpolarized. 
 
Looking forward in the fields of Wlds and neurodegeneration 
 Although my studies have put forth a plausible mechanism for how Wlds 
can protect severed axons, the model still needs rigorous testing to confirm the 
action of Wlds.  The model contains two parts that we believe are important for 
Wlds function, both of which can be tested: (1) mitochondria motility is increased, 
and (2) mitochondrial Ca2+-buffering capacity is increased.  My results have 
already shown that the increase in mitochondrial motility is necessary for Wlds-
mediated axon protection.  However, it remains to be tested if an increase in 
mitochondrial motility alone can suppress Wallerian degeneration.  Although 
there are no known molecules in Drosophila that increase mitochondrial motility, 
there are known ways to increase mitochondria motility in mammals.  Syntaphilin 
is a gene known to be involved in docking stationary mitochondria (MacAskill et 
al., 2009; Cai and Sheng, 2009).  Upon knock out of syntaphilin, there is a great 
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increase in mitochondrial motility (Kang et al., 2008).  Also, simply 
overexpressing Miro in mammalian axons results in an increase in mitochondrial 
movement (Saotome et al., 2008).  Both of these models could be used to test if 
an increase in mitochondrial motility is sufficient for axonal protection after injury.   
The second part of the Wlds model that needs to be tested is the necessity 
for an increase in Ca2+ buffering capacity.  First, results from James Geddes, 
Ph.D. will allow us to say that the biochemistry of Wlds-expressing mitochondria 
has changed.  In order to test if an increase in Ca2+ buffering is necessary for 
Wlds to protect severed axons, we need a way to affect the import of Ca2+ into 
the mitochondria.  LetM1 and MICU1 are two genes that are reported to 
decrease the entry of Ca2+ into mitochondria (Kirchok et al., 2004; Jiang et al., 
2009; Perocchi et al, 2010).  If our model is correct, the mutating either of these 
genes in the presence of Wlds should suppress protection of severed axons.  
There are a few complications that may arise from suppressing the uptake of 
Ca2+ in the mitochondria.  It is possible that an excess of Ca2+ in the cytosol 
produced by blocking mitochondrial Ca2+ uptake would cause spontaneous 
degeneration by activating calpains or other Ca2+-sensitive molecules that may 
drive axon destruction.  Alternatively, if Ca2+ is needed in the mitochondria to 
initiate a death signal, then blocking the uptake of Ca2+ would lead to protection 
of severed axons and have no effect on Wlds.  There is a need for a more 
specific test to only inhibit the action of Wlds and not affect normal cell function.  
However, we can test if increasing mitochondrial calcium buffering capacity can 
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delay Wallerian degeneration.  To test this idea, addition of molecules like 
taurine, which increase calcium buffering capacity, to injured axons should 
suppress degeneration.  We can also test if an increase in mitochondrial calcium 
after axotomy initiates mPTP by inhibiting cyclosporin A, preventing mPTP, and 
thereby protecting a severed axon from degenerating.   
Finally, it remains to be seen if Wlds affects calcium buffering under 
normal circumstances, and if this has an effect on neurotransmission or another 
cellular function.  To test if calcium dynamics are changed without axonal injury, 
octopamine can be applied to my 3rd instar larval fillet preparation with a TdcGal4 
driving gCaMP3 and Wlds.  Additions of octopamine would stimulate Tdc 
neurons, thereby causing an increase in calcium within the cell.  If Wlds increases 
calcium buffering under “physiological” conditions, then a decrease in the 
gCaMP3 signal would be observed when compared to control.  Electrophysiology 
or behavioral tests could show if there is a change in neurotransmission in Wlds-
expressing neurons.  Tests like these would be very important in deciding 
whether Wlds may have some therapeutic possibilities, provided a way to deliver 
the protein or gene was uncovered. 
I have also shown in chapter 4 that we have uncovered a mutant that 
suppresses Wallerian degeneration.  This discovery will open many doors in 
neurodegenerative treatment.  First and foremost, it shows that Wallerian 
degeneration is an active process that can be prevented by inhibiting molecules.  
This is an exciting finding not only for the scientific community, but in terms of 
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creating therapeutic drugs, it is much easier to find small molecule inhibitors than 
to find drugs that enhance a protein or find a way to deliver molecules, like Wlds, 
to the correct cells.  Although we have only uncovered one gene involved in the 
Wallerian degeneration so far, there is a high possibility that more will emerge 
from our EMS mutagenesis screen or a candidate gene approach.  It will be very 
important to analyze the role of Ect-4 not only in axon degeneration, but also in 
other cellular roles to determine if it is a viable target for drug therapies.  Also, as 
more genes from the pathway are uncovered, more therapeutic targets will 
emerge.  
 In my thesis, I have narrowed down the important domains for Wlds 
function to N16 fused to enzymatically active Nmnat1.  I have observed that 
mitochondria in Wlds-expressing axons are more motile, which is the first 
biological change seen in Wlds-expressing axons prior to injury. I further 
demonstrated that this change in mitochondrial trafficking is necessary for full 
Wlds-mediated protection of axons after injury.  I also observed a decrease in 
calcium signal after axotomy in Wlds-expressing axons.  Because of these 
results, I have proposed a model of Wlds function and hypothesized that an 
increase in mitochondrial calcium buffering capacity, which causes an increase in 
mitochondrial motility, is responsible for the ability of Wlds to protect axons after 
degeneration.  I also helped uncover the first Wallerian degeneration loss-of-
function mutant in Drosophila that results in preserved axons after axotomy.  My 
data point to the importance of mitochondria in injury-induced death, and, along 
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with emerging data from neurodegenerative diseases detailing mitochondrial 
dysfunction as a major contributor to disease, highlight the importance of 
studying mitochondria function in health and disease.  The future of the axon 
degeneration field should focus on therapies which can alter the mitochondria or 
a Wallerian degeneration pathway in such a way to save axons from 
degeneration.   
	   156	  
 
 
   Wild-type      WldS 
 
      Fig. 5-1 
	   157	  
Fig. 5-1.  Model of how Wlds affects mitochondria to increase calcium 
buffering.  In the wild-type case, mitochondrial membrane potential is normal, 
therefore the calcium buffering is normal as well.  Upon encountering a high 
amount of calcium, the mitochondria stop until the calcium is cleared from the 
cytosol.  In the case of Wlds, the mitochondrial membrane is hyperpolarized.  
This occurs due to the increase of NAD+ activity of Wlds inside the mitochondria, 
which leads to an increase in proton pumping out of the mitochondria and an 
increase in ATP+ synthesis.  The hyperpolarization of the membrane leads to an 
increase in calcium buffering.  Upon encountering a high amount of calcium, the 
mitochondria quickly buffer the calcium present and so are able to move. 
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